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1. Abstract  
 
Primary open angle glaucoma (POAG), one of the leading causes for blindness in the 
western world, is defined as a progressive optic neuropathy which is characterized by 
the loss of retinal ganglion cells. Various randomized multicenter studies could show that 
an elevated intraocular pressure (IOP), which is too high for the health of the eye, is the 
main risk factor to develop POAG (Collaborative-Normal-Tension-Glaucoma-Study-
Group, 1998; Gordon et al., 2002; Johnson et al., 2002; Leske et al., 2003)  
Today it is widely acknowledged that the increase in IOP is due to a decreased outflow 
facility in the trabecular meshwork (TM). The drainage of aqueous humor in the TM is 
reduced by an increased contractility of TM cells and by an accumulation of extracellular 
matrix (ECM) in the juxtacanalicular TM (Fuchshofer et al., 2007; Lutjen-Drecoll et al., 
2001; Lutjen-Drecoll et al., 1986a; Okka et al., 2004).  
The increase in IOP in combination with structural changes of the ECM in the region of 
the lamina cribrosa (LC) lead to a reduced axonal transport of neurotrophic factors to the 
retina ganglion cells (RGC). The lack of neurotropic factors leads to RGC death which 
causes the neuropathy of the optic nerve and the optical field defects characteristic for 
POAG (Guo et al., 2005); Fuchshofer 2011; Zode et al. 2011). 
Many studies could show that the growth factors TGFβ and CTGF may play an 
important part in the pathogenesis of POAG (Fuchshofer et al., 2005; Fuchshofer, 2011; 
Junglas et al., 2012; Junglas et al., 2009; Tamm & Fuchshofer, 2007). Therefore 
proteins able to inhibit these factors are of high interest as possible therapeutic agents. 
This work focuses on the small leucine-rich proteoglycan Decorin (DCN). DCN inhibits 
TGFβ via direct binding or via the up regulation of Fibrillin 1 synthesis (Neill et al., 2012; 
Yamaguchi, 1990). Possible interactions between DCN, TGFβ and CTGF should be 
analyzed in vitro and in vivo. Further it was aim of this study to analyze if DCN is able to 
inhibit the expression of ECM proteins in cell types involved in the pathogenesis of 
POAG. Additionally it was investigated if the AKT signaling pathway is involved in the 
regulation of TGFβ and CTGF via DCN in optic nerve astrocytes. The final aspect of this 
work was the observation of the effects of a DCN knockout in vivo in the eye in mice of 
mixed background and in mice of a pure CD1 background.  
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The experiments showed that a treatment with TGFβ and CTGF leads to a decreased 
synthesis and expression of DCN in various cell types of the eye which play an 
important part in the development of POAG. On the other hand, a treatment with DCN 
led to a decreased synthesis of TGFβ-1, TGFβ-2 and CTGF in these cell types. 
Additionally, the synthesis of ECM proteins Fibronectin and Collagen IV was down 
regulated after treatments with DCN. We could further show that DCN regulates TGFβ-
1, TGFβ-2 and CTGF via the AKT signaling pathway. 
Interestingly we were not able to cultivate optic nerve astrocytes of DCN knockout mice, 
while optic nerves astrocytes of wildtype littermates grow well in culture.  
Immunohistochemical staining showed reduced levels of DCN in the TM of 
glaucomatous eyes in comparison to the TM of healthy donors.  
In vivo a lens specific overexpression of CTGF, which leads to the development of 
POAG (Junglas et al., 2012) resulted in a reduced DCN Expression in the region of the 
TM, but not in the optic nerve.   
The eyes of DCN knockout mice showed a significant increase in IOP and a significantly 
reduced number of axons, which are typical characteristics of POAG. These might be 
due to the enhanced expression of TGFβ, CTGF and ECM proteins in the chamber 
angle, which could be observed on RNA and protein level. Furthermore levels of pAKT 
were reduced in the TM, the retina and in the glial lamina of DCN knockout mice. 
The results show a clear interaction between DCN and TGFβ/CTGF as between DCN 
and ECM-Proteins in vitro and in vivo. DCN seems to play an important role in inhibiting 
processes which can cause POAG. It possibly causes the balance between the 
necessary and pathogenic expression of TGFβ, CTGF and ECM proteins in the eye.  
The results lead to the conclusion that DCN is a highly promising candidate for a 
therapeutic against POAG. It will be of high interest to observe the effects of DCN 
treatments or an adenoviral gene transfer of DCN to the eyes of βB1-CTGF and DCN 
knockout mice. We hypothesize that such treatments will lead to a decrease in IOP and 
to a reduction of axonal loss.  
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2. Introduction  
 
Glaucoma is a group of eye diseases which are defined as an optic neuropathy that 
leads to visual field defects or even to complete blindness. In 2013 glaucoma affected 
about 64.3 million people worldwide and it is estimated that the number of patients will 
increase to 111.8 million by 2040. Different forms of glaucoma are classified by the 
appearance of the iridocorneal angle. With about 44.1 million cases in 2013 primary 
open angle glaucoma (POAG) is the most common form. (Tham et al., 2014).  
In POAG the iridocorneal angle remains open at all times and multiple randomized, 
prospective multicenter studies have clearly shown that an increased IOP is the main 
risk factor to develop POAG (Collaborative-Normal-Tension-Glaucoma-Study-Group, 
1998; Gordon et al., 2002; Johnson et al., 2002; Leske et al., 2003). An IOP that is too 
high for the health of optic nerve leads to the death of retinal ganglion cells (RGC). RGC 
death causes scomtomas or in severe cases complete blindness. Since the molecular 
reasons causing elevation of IOP and RGC death are poorly understood it is of great 
interest to identify key players in these processes – proteins or other molecules that 
might contribute to the pathological changes occuring in the eye in POAG.  
 
2.1 Trabecular meshwork and aqueous humor outflow  
 
IOP is build up by the circulation of aqueous humor (AH). A healthy IOP is ensured by a 
balance of AH production by the ciliary body and AH drainage through the trabecular 
meshwork (TM). The TM lies embedded in the iridocorneal angle and is a sponge-like 
structure which enables the drainage of AH into the episcleral venous system.  
The AH, secreted by the ciliary body, is essential for the stability and the form of the eye 
and nourishes the lens, the cornea and the TM. It flows from the ciliary body in the 
posterior chamber through the pupil into the anterior chamber were it passes the TM and 
drains into Schlemm’s canal (SC). Between the TM and SC the outflow resistance is 
located. If the production and drainage of AH are in balance an IOP of between 11 and 
21mm Hg is created. The aqueous humor mainly drains through the trabecular  
(= conventional) outflow pathway, only small amounts drain via the  
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uveoscleral (= nonconventional) outflow pathway. In this pathway the AH drains by 
diffusing through intracellular spaces between ciliary muscle fibers (Bill and Phillips, 
1971).  
 
 
Figure 1: Circulation of aqueous humor. The AH is secreted by the ciliary body and then flows through 
the pupil from the posterior into the anterior chamber. It then leaves the anterior chamber via the TM and 
drains in Schlemm’s canal which leads into the episcleral venous system (Kwon et al., 2009b). 
 
The TM spans from the scleral spur the Schwalbe’s line, representing the separation 
between corneal endothelium and TM and can be divided into three different parts: the 
inner uveal meshwork, the corneoscleral meshwork and the juxtacanalicular tissue (JCT) 
or cribriform meshwork.  
The uveal meshwork consists of densely packed bundles of fibers, which terminate on 
one side in the hyaline substance, forming the Descement’s membrane, and are firmly 
attached to the connective tissue of the iris root and the ciliary muscle on the other side 
(Speakman, 1959). It consists of about 3 layers of connective tissue beams, the 
trabecular beams, which are covered by flat confluent TM cells and form irregular 
intratrabecular fenestrations. These beams can also be found in the corneoscleral 
meshwork but not in the JCT. The corneoscleral meshwork is formed by 8 to 15 layers of 
beams covered by TM cells. These beams form intratrabecular spaces giving it a 
sponge-like structure. The outer beam cells of these regions are highly phagocytic and 
are seen as a sort of pre-filter, removing debris from the AH.  
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The intratrabecular spaces become smaller as they extend closer to the SC. The 
intratrabecular spaces in the uveal- and corneoscleral meshwork are too wide to hinder 
aqueous humor flow, meaning that in this region almost no outflow resistance is created 
(Buller et al., 1990; Overby et al., 2009; Rohen and van der Zypen, 1968; Sherwood and 
Richardson, 1988). 
In the region of the JCT the structure is inherently different. The JCT cells form a 
discontinuous cell layer without pores (Lutjen-Drecoll, 1999; Lutjen-Drecoll et al., 1981; 
Tamm, 2009). The cells of the JCT are star-shaped and form contacts between the TM 
beam cells and the endothelial cells of SC. The 2 to 5 amorphous and discontinuous cell 
layers lie embedded in a loose connective tissue ECM. The ECM in this region consists 
mainly of proteoglycans, hyaluronan (HA), laminin, Collagen Type IV (Col IV) and 
Fibronectin (FN) (Tamm, 2009; Tawara et al., 1989; Ueda et al., 2002) and most of 
these proteins are expressed by the JCT cells (Fuchshofer et al., 2006). Tangentially to 
the SC endothelial lining lies a network of elastic fibers, the cribriform plexus. These 
fibers connect with the SC inner wall endothelium via their sheath material or via fine 
fibrils. Anterior tendons of the ciliary muscle anchor in the cribriform plexus. Thereby 
ciliary muscle contraction may influence the width of the JCT and its intracellular spaces 
and so have an effect on aqueous humor outflow (Rohen et al., 1981; Rohen et al., 
1984).  
The inner wall endothelium of SC forms giant vacuoles, where the basal membrane of 
the endothelium is discontinuous. In these regions the basal membrane is connected to 
the JCT. The structure of the TM and experimental flow studies indicate that about 90% 
of AH outflow resistance is created in the region of the JCT and the inner wall of SC (Bill 
and Phillips, 1971; Ethier et al., 1986; Overby et al., 2009; Rohen et al., 1981; Tripathi, 
1971). AH has to cross the endothelium of SC through micron-sized pores, separated by 
fairly wide distances (20-30µm). This leads to a non-uniform flow pattern, since AH must 
“funnel” as it approaches a pore. Hence flow patterns in the JCT have to be non-uniform, 
too. The non-uniform flow decreases the area effectively available for passage, leading 
to an increase in the hydraulic resistance of this region (funneling hypothesis) (Johnson 
et al., 1992; Overby et al., 2009). 
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Figure 2: Meridional section through the trabecular meshwork. (B) is a magnification of (A). SC: 
Schlemm’s Canal, TM: Trabecular meshwork, SS: Scleral spur, CM: Ciliary muscle, AC: Anterior chamber, 
JCT: Juxtacanalicular tissue, CTM: Corneoscleral TM, UTM: Uveal TM; Arrows in (B) point to vacuoles in 
the inner wall of SC. Scale bars 20 mm (A), 5 mm (B) (Tamm, 2009). 
 
TM cells play a pivotal role in the continuous synthesis of ECM components in the 
chamber angle. ECM turnover and composition are thought to play a crucial part in the 
formation of outflow resistance (Acott and Kelley, 2008; Johnson, 2006). This hypothesis 
is underscored by findings that the turnover of ECM by matrix metalloproteinases 
(MMPs) is essential for the maintenance of AH outflow (Bradley et al., 2001; Bradley et 
al., 1998; Keller et al., 2009).  
Outflow resistance can also be regulated via changes in the tonus of the actomyosin 
contractility of TM cells. Thereby the TM can be relaxed or contracted and an increase in 
TM tone increases outflow resistance (Tian et al., 2000; Wiederholt et al., 2000). 
Additionally the width of SC and also the contribution of pores formed by SC cells 
influence outflow facility and heterogeneity (Allingham et al., 1996; Braakman et al., 
2015). 
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Since human TM samples are very rare and can only be analyzed post mortem or in 
organ culture, animal models are of high interest for glaucoma research. In human TM 
organ culture there is no possibility to observe the effects of over-expression or knockout 
of genes of interest in the TM on RGCs and ON axons. In animal models on the other 
hand, one can observe effects on all tissues involved in POAG and the time course of 
structural changes. In mice the structure of the TM and SC, as well as the connection 
between the TM and the inner wall of the SC, is similar to primates, whereas for 
example the porcine and bovine TM differ from the primate TM. The porcine TM is 
mostly formed by an angular aqueous plexus (McMenamin and Steptoe, 1991) and 
cows do not have a lamellate meshwork but a reticular meshwork (Chen et al., 2008). 
This makes mice the most usable model for outflow regulation and ECM changes in the 
TM as relevant for glaucoma (Overby et al., 2014a)  
 
2.2 Optic nerve and lamina cribrosa 
 
Besides the TM, the region of the optic nerve head (ONH) and the lamina cribrosa (LC) 
undergo the most dramatic changes in POAG. The optic nerve (ON) is formed by the 
axons of RGCs, which lie in the innermost layer of the retina, and is responsible for the 
transduction of signals from the retina to the brain. The region, were the RGC axons 
leave the eye, is called papilla. Since the ON derives from an out-pouching of the 
diencephalon (optic stalks), it is not a cranial nerve in the narrow sense. That is why it is 
covered by dura mater, which merges into the sclera.  
Astrocytes are the most common form of glial cells in the optic nerve and they are vital 
for RGC health. In the mid-19th century they were first described as some kind of filling 
material by Von Virchow in 1846. Today it is known that astrocytes maintain the 
homeostatic balance of the extracellular environment by absorbing or degrading 
substances dispensed by neurons. Furthermore, they are an essential part of the blood-
retina barrier (Ransom et al., 2003). Astrocytes supply neurons with nutrients by 
clasping around blood vessels and connecting them to neurons (Bouzier-Sore and 
Pellerin, 2013) and they can influence neuronal tissue by restructuring the ECM and 
releasing growth factors, cytokines and other cellular mediators under normal and 
pathologic conditions (Hernandez, 1992, 2000; Hernandez et al., 1994).  
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Additionally to the glial fibrillary acid protein (GFAP) positive astrocytes, 
oligodendrocytes, sheathing the RGC axons and microglia cells can be found in the ON. 
Astrocytes can be classified into ~11 distinct phenotypes that can be readily 
distinguished regarding their expression profile and morphology (Abbott et al., 2006). In 
the human ON three subtypes of astrocytes were identified. Type 2 astrocytes are the 
dominant subtype in the myelinated postlaminar part of the ON and type 1 astrocytes 
are the main subtype in the unmyelinated laminar and prelaminar region of the ON 
(Kobayashi et al., 1997; Ye and Hernandez, 1995).  
In humans, where the RGC axons leave the eye, a sieve- like structure formed by many 
layers of collagen fibers, the LC (see Fig. 3 C) is located. The LC is essential to give the 
optic nerve head (ONH) a certain amount of elasticity to protect the axons from 
mechanical stress (Albon et al., 2000). Furthermore, it provides structural and functional 
support to the axons. The LC is a complex three-dimensional network of flexible 
connective tissue beams. The connective tissue beams in humans are composed of 
proteoglycans, laminin, FN, Col I, III, IV, V and VI and elastic fibers (Goldbaum et al., 
1989; Morrison et al., 1989a; Morrison et al., 1989b). Besides Astrocytes, mostly GFAP 
negative, fibroblast like LC cells are present in this region. Together with the astrocytes 
these cells are involved in the composition of the LC and are responsible for the 
maintenance of ECM, by synthesizing, for example, Col III and IV, FN and Elastin (EL) 
(Hernandez et al., 1988). 
Type 1 astrocytes and the LC cells form the cribriform plates of the LC. LC cells are 
located inside the plates of the LC (Hernandez, 1992, 2000; Kobayashi et al., 1997). In 
the LC and in the prelaminar region the processes of the astrocytes sheath axon 
bundles, surround blood vessels and link connective tissue surfaces (Anderson, 1969). 
In mice, instead of a LC and LC cells, astrocytes form a glial lamina, which takes over 
the supporting function for axons (Sun et al., 2009).  
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Figure 3: Graphical illustration of the LC. A: Diagram of the anatomy of the eye with the location of the 
papilla and the ON. B: Histological tangential section through the scleral canal and ONH showing the 
peripapillary sclera, Lamina cribrosa, and retinal ganglion cell axons (Downs et al., 2003), C: 3D 
reconstruction of the LC, illustrating regional variation in connective tissue density and predominant 
laminar beam orientation throughout the laminar structure (adapted from Sigal et al., 2010).  
 
2.3 The pathogenesis of primary open angle glaucoma  
 
Like all types of glaucoma, POAG is defined as a progressive optic neuropathy that is 
characterized by an irreversible loss of RGC axons in the ON. During the progression of 
POAG the region of the TM and the ONH, especially the LC, undergo drastic changes.  
 
2.3.1 Pathological changes in the trabecular meshwork  
Some of the changes occurring in the chamber angle can be observed by electron 
microscopy. In the JCT of glaucomatous eyes increased amounts of plaque material 
were observed (Gottanka et al., 1997; Lutjen-Drecoll et al., 1986a, b; Tektas and Lutjen-
Drecoll, 2009). From the sheath of these plaques, connecting fibrils extend, which link 
the SC endothelial cells to JCT cells (Fuchshofer et al., 2006; Hann and Fautsch, 2011). 
In eyes of glaucomatous donors the sheath of the plaques are thickened and the 
connecting fibrils show increased amounts of Col IV and other ECM components. In 
severe cases the fibrils form fibrous plates and it is thought that this could contribute to 
the blocking of outflow pathways (Lutjen-Drecoll et al., 1981). Further the area occupied 
by plaques in the JCT correlates with axonal loss in the ON (Gottanka et al., 1997). All in 
all it is accepted today that the increase in ECM material in the TM leads to a reduction 
of AH outflow and increases IOP (Tamm and Fuchshofer, 2007). 
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The second regulatory mechanism of AH outflow, the actomyosin contractility of TM 
cells also seems to be disturbed in POAG. These changes show in stiffening of the TM 
in POAG. The glaucomatous TM is approximately 20 times stiffer than the TM of healthy 
eyes, but it is still unclear whether this is due to an increase in TM cell stiffness or ECM 
stiffness (Last et al., 2011). Treatments with dexamethason, a corticosteroid that 
elevates IOP in up to 40% of normotensive eyes and in almost all POAG eyes (Clark et 
al., 2002; Lewis et al. 1988; (Bollinger et al., 2012), lead to a remarkable stiffening of TM 
cells and their ECM (Raghunathan et al., 2015). The important role of actomyosin 
contractility in AH outflow regulation could further be shown in studies using latrunclin. 
Latrunculin inhibits the formation of actin microfilaments, which results in cellular 
relaxation, and can therefore increase outflow of AH in the TM and lower IOP (Ko et al., 
2016; Okka et al., 2004; Rasmussen et al., 2014).  
2.3.2 Pathological changes in the optic nerve head and lamina cribrosa  
 
In the ONH region an ECM remodeling process occurs, leading to a stiffening of the 
peripapillary sclera (Coudrillier et al., 2012), thickening of the connective tissue sheaths 
around the capillaries (Tektas et al., 2010) and a restructuring of the LC (Pena et al., 
1998; Quigley et al., 1991b; Quigley et al., 1983). The elastic fibers of the LC show 
marked changes as the fibers are no longer organized straightly, but appear curly and 
seem to be disconnected from the adjacent ECM material (Netland et al., 1995; Pena et 
al., 1998; Quigley et al., 1991a). The changes of elastic fibers are associated with a 
restructuring of the collagen network, including qualitative and quantitative changes in 
the distribution and density of collagen fibers in the laminar beams (Hernandez et al., 
1991; Quigley et al., 1991b). Those ECM alterations of the LC may form the biochemical 
basis for a stiffer and less resilient structure, leading to a decrease in mechanical 
compliance of the LC in glaucoma (Albon et al., 2000). The structural alterations in 
conjunction with the increased IOP lead to cupping of the ONH and backward bending of 
the LC, typical symptoms observed in POAG (Quigley, 2011). Combination of all these 
factors seems to inhibit antero – and retrograde axonal transport of neurotrophic factors 
in the region of the LC and depravation of neurotrophic factors induces death of RGCs 
(Pease et al., 2000; Quigley et al., 2000).  
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Figure 4: Histological sections of the ONH.  A: a typical histological section through a healthy ONH. B: 
histological section through the ONH of a glaucoma patient. The ONH shows the typical excavation of the 
ONH (Quigley, 2011). 
 
One question glaucoma research focused on during the last decades is what the source 
of these increased amounts of ECM material in the ONH and the LC is. Today it is 
widely acknowledged that mainly astrocytes are responsible for the production of ECM 
material in the ONH (Hernandez, 1992, 2000; Hernandez et al., 2002). It is suggested 
that reactivated astrocytes are heavily involved in the restructuring process within the 
LC. In situ hybridization experiments show that astrocytes in glaucomatous ONH 
express higher levels of collagen type IV than astrocytes of non-affected ONH 
(Hernandez et al., 1994). Further microarray analysis of cultured human ONH astrocytes 
from normal and glaucomatous donors could demonstrate that glaucomatous human 
ONH astrocytes have increased expression levels of different ECM proteins, including 
laminin, fibulin and collagen type-II, IV and XI, whereas the proteoglycans, like for 
example aggrecan, were downregulated (Hernandez et al., 2002; Lukas et al., 2008). 
Under normal conditions astrocytes of the ONH are in a quiescent state, but during the 
cause of glaucoma they undergo a process of reactivation called astrogliosis. 
Astrogliosis shows in alterations in astrocyte morphology, like thickening of processes 
and hypertrophy of the cell body. In human ONH with chronically elevated IOP and 
moderate or advanced glaucomatous axonal damage astrocytes show these 
morphological changes and an increased immunoreactivity for GFAP (Hernandez and 
Pena, 1997; Varela and Hernandez, 1997; Wang et al., 2002).  
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The molecular reasons for these pathological processes are complex and are only 
partially elucidated. One molecule that has been in the focus of glaucoma research for 
many years is the transforming growth factor (TGF-) β. Especially TGF-β2 was found in 
elevated levels in the aqueous humor of glaucoma patients (Inatani et al., 2001; Ochiai 
and Ochiai, 2002; Picht et al., 2001; Tripathi et al., 1994b; Yamamoto et al., 2005) and it 
is known to be involved in the pathogenesis of various fibrotic diseases, like for example 
in the liver (Baghy et al., 2012; Hellerbrand et al., 1999; Kanzler et al., 1999; Ueberham 
et al., 2003) or the kidney (Sharma and Ziyadeh, 1994; Yamamoto et al., 1993; Ziyadeh, 
1994) but also in the eye (Jester et al., 1997; Karamichos et al., 2010).  
 
2.4 TGF-β and CTGF - key players in primary open angle glaucoma  
 
In eukaryotes three different isoforms, TGF-β1, 2 and 3 are encoded by a distinct gene. 
In the eye TGF-β2 is the most expressed isoform and it is expressed in multiple eye 
tissues (Cousins et al., 1991; Jampel et al., 1990; Pasquale et al., 1993; Pena et al., 
1999). The major part of the TGF-β is produced by the epithelium of the ciliary body and 
the lens and then secreted to the AH (Allen et al., 1998; Helbig et al., 1991; Jampel et 
al., 1990; Pasquale et al., 1993; Schlotzer-Schrehardt and Dorfler, 1993). Nevertheless 
also TM cells and astrocytes of the optic nerve head are able to express and secrete 
TGF-β (Pena et al., 1999; Tripathi et al., 1994a).  
Members of the TGF-β superfamily act as cytokines and can therefore be involved in 
various processes in the cell. Depending on cell status and tissue they can for example 
influence proliferation, differentiation and apoptosis, but are also involved in cell 
adhesion, embryogenesis, angiogenesis and immune suppression. TGF-β is 
synthesized as a pro-TGF-β molecule which contains the latency-associated proteins 
(LAP) and the latent TGF-β binding proteins 1 and 2 (LTBP1/2) connecting the whole 
complex to the ECM (Nunes et al., 1997). The release of active TGF-β from this 
complex can take place through proteolytic activity by plasmin, MMP2 and MMP9, 
through integrins or through the action of thrombospondin (Munger et al., 1997; Munger 
et al., 1999; Murphy-Ullrich and Poczatek, 2000; Sato and Rifkin, 1989; Yu and 
Stamenkovic, 2000).  
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Classical TGF-β signaling starts with binding of TGF-β to TGF-β receptor type II (TGF-β 
RII) which gets phosphorylated and binds to TGF-β receptor type I (TGF-β RI). Upon 
binding the TGF-β RI is activated which leads to a phosphorylation of Smad2 and 
Smad3 (pSmad = small mothers against decapentaplegic). The pSmad2/Smad3 
complex dissociates from the receptor and binds Smad4. This complex translocates into 
the nucleus where it can either activate or inactivate the expression of TGF-β target 
genes (Derynck and Zhang, 2003).  
If present in physiological concentrations in the eye, TGF-β is essentially involved in the 
immune privilege by oppressing the production of interferon γ (IFN- γ) and interleukin 4 
(IL-4), which leads to oppression of the immune system (Ohta et al., 2000a; Ohta et al., 
2000b; Streilein, 1999a, b; Taylor et al., 1997).  
Pathological levels of TGF-β in the AH, as stated above, are seen as one of the major 
causes for the pathological changes occurring in the ONH and the TM in POAG 
(Fuchshofer et al., 2005; Fuchshofer and Tamm, 2009; Fuchshofer et al., 2007; 
Neumann et al., 2008; Zode et al., 2011). In cultured human TM cells treatment with 
TGF-β2 leads to an increased expression of various ECM proteins, including FN, Col 
and Elastin (El). Additionally TGF-β can increase amounts of ECM by inhibiting proteins 
that degrade ECM components. For example synthesis of plasminogen activator 
inhibitor-1 (PAI-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) is elevated after 
TGF-β2 treatment, leading to a decreased activity of MMP2 (Fuchshofer et al., 2003). 
Those proteins inhibit proteolytic degradation of ECM components, meaning  an 
elevated activity would lead to an increase in ECM accumulation (Fuchshofer and 
Tamm, 2009). In ex-vivo perfused anterior eye chambers TGF-β2 leads to a decreased 
AH outflow rate, most likely by the observed increase of FN, PAI-1 and the accumulation 
of fibrillary material (Fleenor et al., 2006; Gottanka et al., 2004). Further, adenoviral 
gene transfer of TGF-β2 causes an elevation of IOP in mice and rats. In mice it could be 
proven that the AH outflow facility is reduced and the grade of ocular hypertension 
correlates with TGF-β2 expression level in this mouse model (Shepard et al., 2010).  
Regarding the ONH, treatments with TGF-β2 lead to an increased expression and 
synthesis of EL, Col I, Col IV, Col VI and FN in astrocytes via the canonical Smad 
signaling pathway (Fuchshofer et al., 2005; Neumann et al., 2008; Zode et al., 2011). In 
situ TGF-β2 levels are elevated in the ONH of glaucoma patients and it was shown that 
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its source are mostly astrocytes in the prelaminar region (Pena et al., 1999; Zode et al., 
2011). Experiments with LC cells provided the same results. In this cell type treatments 
with TGF-β2 lead to an increased expression and syntheses of ECM components, 
similar to those observed in the TM (Kirwan et al., 2005; Kirwan et al., 2009; Zode et al., 
2011). 
TGF-β’s downstream mediator CTGF is also strongly involved in the pathogenesis of 
POAG. It is able to induce restructuring of the ECM, either alone or together with TGF-β, 
in the TM (Junglas et al., 2009). The 38kDa large protein belongs to the CCN-family 
(CTGF, cysteine-rich angiogenic protein 61, nephroblastoma overexpression gene and 
wnt inducible pathway protein 1 – 3) and is therefore also known as CCN2. Members of 
the CCN family are involved in various cellular processes like adhesion, proliferation, 
differentiation and survival and also in biological processes like angiogenesis, 
chondrogenesis, tumorogenesis and wound healing (Brigstock, 2003).  
Data on CTGF concentration in the AH of POAG patients is slightly controversial. One 
study shows that CTGF levels are slightly increased in the AH of POAG patients, while 
CTGF levels in AH of patients with pseudoexfoliation (PEX) glaucoma are considerably 
increased(Browne et al., 2011). Another study shows highly elevated levels in the AH of 
POAG and pseudoexfoliation (PEX) glaucoma patients (Fahmy, 2008). CTGF influences 
ECM reorganization and the actin cytoskeleton. In the anterior eye segment TM cells 
and SC cells are able to produce CTGF and this production can be increased in TM cells 
by treatment with TGF-β1 or via high pressure perfusion (Chudgar et al., 2006). 
Furthermore SC cells of glaucomatous donors express significantly more CTGF than 
those of healthy controls (Overby et al., 2014b) and TM cells react to stiffer substrates 
with an upregulation of CTGF expression (Raghunathan et al., 2013). In recent studies 
our group could show that actually most effects of TGF-β on TM ECM are mediated by 
CTGF (Junglas et al., 2009) and that CTGF modulates the biological properties of the 
actin cytoskeleton increases its contractility (Junglas et al., 2012).  
Astrocytes of the ONH do not show accumulation of ECM when treated with TGF-β2 
after a knockdown of CTGF. This shows that in this region, too, the fibrotic effects of 
TGF-β2 depend on the presence of CTGF (Fuchshofer et al., 2005). 
In mice a lens-specific overexpression of CTGF leads to glaucomatous changes with 
elevated IOP and a loss of RGC axons in the optic nerve. This effect is most likely 
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mediated by the modification of the actin cytoskeleton in the TM. Additionally, levels of 
FN and smooth muscle actin alpha (α-SMA) are increased in the iridocorneal angle of 
this mouse model (Junglas et al., 2012). The effects of the CTGF overexpression mimic 
the pathological changes occurring in human eyes in POAG. That makes these mice an 
applicable model for POAG and gives us the opportunity to investigate molecular factors 
involved in the pathogenesis of this disease.   
All these findings show the essential role that TGF-β and CTGF are playing in the 
pathological changes occurring in the TM and the ONH of POAG patients. Since both 
growth factors are present in a healthy eye and fulfill essential roles there, we 
hypothesize that endogenous antagonists are necessary to keep the balance between 
physiological and pathological concentrations of TGF-β and CTGF. Due to that it is of 
great importance to identify these possible antagonists which might be able to interfere 
with TGF-β’s and CTGF’s pathological effects in the eye.  
 
2.5 Decorin – an antagonist of TGF-β and CTGF  
 
DCN is probably the best-studied member of the small leucine-rich proteoglycan (SLRP) 
family, which includes 18 distinct members in five discrete classes. The protein family is 
characterized by multiple adjacent domains bearing a leucine-rich repeat (Hocking et al., 
1998). Sequences of SLRPs are conserved across multiple species (McEwan et al., 
2006; Neill et al., 2012; Schaefer and Iozzo, 2008). The name Decorin is due to its close 
interaction with collagen fibers that could be seen as “decoration”. DCN was initially 
cloned and named PG40 in 1986 and first seen as a mere structural component of the 
ECM (Krusius and Ruoslahti, 1986). It was discovered that DCN actually plays essential 
parts in differentiation, proliferation, spreading and migration and that it is further an 
important regulator of inflammation (Border et al., 1992; Yamaguchi et al., 1990; 
Yamaguchi and Ruoslahti, 1988). 
DCN is about 90 kDa in size and contains a core protein of about 40 kDa and a single 
glycosaminoglycan (GAG) side chain of about 50 kDa consisting of either dermatan or 
chondroitin sulfate. 12 leucine rich repeats (LRRs) are located in the core protein, 
presenting the typical element of all SLRPs. The protein is divided into four different 
domains. The first domain contains the signaling peptide and the propeptide, the second 
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consists of four cysteine residues to which the GAG-sidechain can bind. In the third 
domain there are the leucine-rich repeats and the fourth domain contains again two 
cysteine residues, which form a big loop (Iozzo, 1998). 
The crystalline structure of DCN is horseshoe-shaped. The concave area is formed by a 
β-leaflet while the convex area is formed by α-helices. Binding to the collagen triple helix 
is achieved by the core proteins’ inner concave surface (Scott, 1996; Weber et al., 
1996). This binding of collagen fibers is essential for a normal organization of the ECM 
and for the stability of connective tissue. In mice with a homozygous knockout of DCN 
wound healing is significantly slowed and formation of scare tissue is increased.  
In comparison to wildtype animals the dermis of DCN knockout (DCN-/-) mice is thinner 
and the expansibility of collagen fibers is reduced (Danielson et al., 1997). Also fibrotic 
processes are enhanced in DCN-/- mice. For example thioacetamide-induced liver 
fibrosis is significantly stronger and takes longer to heal than in wildtype mice (Baghy et 
al., 2011). DCNs’ inhibitory effect on cell division could also be demonstrated in  
DCN-/- mice. In contrast do wildtype mice fibroblast numbers in the periodontal ligament 
are doubled in DCN-/- mice (Hakkinen et al., 2000).  
 
 
Figure 5: Schematic drawing of DCN structure (A) and binding model to C (B).  DCN consists of 12 
leucine rich repeats, 6 cysteine residues, a GAG side chain and a variable number of n-linked 
oligosaccharides (A). Collagen fibrils are assembled into a collagen bundle by the antiparallel complex of 
the CS/DS hybrid GAG chains of Decorin (B) (Kosho, 2013).  
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One property that brought DCN in the focus of much research during the last years is its 
strong involvement in tumor growth. In vivo about 30% of DCN-/- mice develop 
spontaneous intestinal tumors (Bi et al., 2008). Furthermore DCN expression is 
drastically reduced or completely absent in tumors when compared to expression levels 
of normal tissue (Bozoky et al., 2014; Liang et al., 2013).   
In the eye DCN is present in cornea, retina and TM (Funderburgh et al., 1998; Inatani et 
al., 1999; Tanihara et al., 1995). Regarding POAG DCN is of special interest since it is 
able to bind TGF-βs and CTGF and thereby inhibit their profibrotic effects. In 1990 it was 
demonstrated that Chinese hamster ovary cell growth is inhibited in the presence of 
DCN and that this is due to the fact that DCN binds TGF-β, which is necessary for 
growth in this cell type (Yamaguchi et al., 1990). If DCN is bound to the ECM, it may 
scavenge TGF-βs directly and therefore prevent their interaction with TGF-β RII 
(Yamaguchi et al., 1990). On the other hand, soluble DCN is able to bind to insulin-like 
growth receptor I (IGF-IR), an effect that subsequently leads to an upregulation of 
Fibrillin-1 (FBN1) synthesis via the activation of the pAKT/AKT pathway (Kaartinen and 
Warburton, 2003; Schonherr et al., 2005). FBN1 is necessary for the control of TGF-β 
activation, as it controls the assembly and stability of the latent TGF-β complex (Annes 
et al., 2003). Clearly, the modulation of TGF-β signaling by DCN will indirectly take 
influence on that of its downstream mediator CTGF, but there is also evidence that DCN 
is able to bind to CTGF at LRR 10 - 12 and thereby inhibit its effects on ECM expression 
and synthesis and its capability to induce actin stress fiber formation (Vial et al., 2011).  
The regulatory effects of TGF-β on DCN seem to be cell type dependent. In human skin 
fibroblasts and human chondrocytes TGF-β down-regulate DCN expression (Kahari et 
al., 1991; Roughley et al., 1994). In murine osteoblasts, on the other hand, TGF-β1 
leads to an upregulation of DCN expression (Takeuchi et al., 1993) and the same effect 
was observed in rat mesangial cells (Border et al., 1990).  
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Figure 6: TGF-β inhibition by DCN.  Matrix bound DCN (A) binds to directly TGF-β, the canonical TGF-β 
signaling pathway can’t be activated by binding of TGF-β to TGF-β RII. Soluble DCN (B) binds to IGF-IR, 
Fib 1 translation is upregulated and TGF-β is neutralized (Akhurst, 2006; (Schaefer, 2011). 
 
In the eye, DCN has, up till now, mostly been studied in the context of corneal haze 
formation, because a mutation in the encoding gene may lead to congenital stromal 
corneal dystrophy, a condition that is characterized by the presence of corneal opacities 
which become visible at or shortly after birth (Rodahl et al., 2006). The phenotype may 
lead to corneal scaring and blindness, a process that is typically associated with and 
enhanced by increased TGF-β signaling. There is evidence that tissue-specific viral 
gene transfer of DCN by means of AAV-5 DCN gene therapy inhibits corneal scarring 
significantly (Mohan et al., 2011) and that this is due to an inhibitory effect of DCN on 
TGF-β in corneal fibroblasts (Mohan et al., 2010).  
More recently, it was shown that SC cells of glaucomatous donors express significantly 
lower amounts of DCN than SC cells of healthy controls but that DCN is more strongly 
upregulated by stiffer substrates in glaucomatous SC cells (Overby et al., 2014b). In 
accordance to this, the ECM deposited of HTM cells treated with dexamethasone is 
about 4-fold stiffer and contains elevated levels of DCN compared to the ECM of 
untreated controls (Raghunathan et al., 2015). Till now, it is unclear if DCN serves as a 
kind of rescue mechanism against too high levels of TGF-β and CTGF in the eye and if 
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the presence of too little DCN favors the onset of POAG, but in rats with TGF-β induced 
hypertension intravitreal injections of DCN lowered IOP and reduced RGC loss by 
reducing ECM accumulation in the TM (Hill et al., 2015). These findings make DCN a 
highly interesting candidate for lowering IOP and preventing or slowing down the onset 
and progression of POAG.  
2.6 Aims of the study  
 
The aim of this study is to investigate the reciprocal effects of TGF-β2, CTGF and DCN 
in ocular cell types involved in the pathogenesis of POAG. Further it is of interest to 
clarify whether DCN is able to reduce the expression and synthesis of ECM components 
in these cell types.  
Since murine ON astrocytes are easier to receive than human ON astrocytes we want to 
find out if murine ON astrocytes react in the same way to TGF-β2, CTGF and DCN 
treatments as human ones. Additionally this cell line is used to analyze via which 
pathway DCN influences TGF-β and CTGF expression.  
In vivo, this study focuses on two different mouse models. βB1-CTGF mice are used to 
investigate the effects of a lens-specific overexpression on DCN expression and 
synthesis in TM and ON. DCN-/- mice are studied to confirm our hypothesis that a lack of 
DCN in the eye leads to elevated levels of TGF-β2 and CTGF and thus to elevated IOP 
and loss of exons. 
The following experiments were carried out to achieve these aims: 
 Analysis of DCN levels in the chamber angle of eyes of glaucomatous and 
healthy donors  
 Evaluation of reciprocal effects of TGF-β2, CTGF and DCN in human TM cells, 
human ONH astrocytes and murine ON astrocytes. 
 Analysis of FN and Col IV expression and synthesis after DCN treatment in 
human TM cells and human ONH astrocytes. 
 Analysis of the effects of inhibiting the AKT-pathway on DCN ability to regulate 
TGF-β and CTGF. 
 Analysis of DCN levels in the corneo-scleral ring, the ON and the ONH of βB1-
CTGF mice. 
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 Analysis of TGF-β, CTGF, FN and Col IV levels in the corneo-scleral ring and the 
ON of DCN-/- mice. 
 IOP measurements of DCN-/- mice and their wildtype littermates of different ages 
and in different backgrounds 
 Quantification of optic nerve axons of DCN-/- mice and their wildtype littermates of 
different ages and in different backgrounds 
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3. Materials and methods 
 
3.1 Materials 
3.1.1 Reagents 
Designation Source of supply 
0.05 % Trypsin/EDTA  PAA The Cell Culture Company, Pasching, 
Austria  
10 x PCR-Buffer  Qiagen, Hilden, Germany 
2-Mercaptoethanol  Roth, Karlsruhe, Germany  
2,4,6-Tri(dimethylaminomethyl)phenol (DPM-
30)  
Roth, Karlsruhe, Germany 
2-Dodecenylsuccinic-acid-anhydride (DDSA)  Roth, Karlsruhe, Germany 
Acetic acid, glacial  Merck, Darmstadt, Germany 
Acetone Merck, Darmstadt, Germany 
Albumin Fraction V (BSA)  Roth, Karlsruhe , Germany 
Agarose  Biozym Scientific, Oldendorf, Germany 
Ammonium persulfate (APS), 10% (w/v)  Roth, Karlsruhe, Germany  
Astrocyte growth supplement (AGS)  Sciencell, Carlsbad, USA 
BC Assay Reagent A+B  Interchim, Wörgl, Österreich  
BC Assay Reagent 1+2 Roth, Karlsruhe, Germany 
Casyton  Roche/Innovatis, Bielefeld, Germany 
CDP-Star  Roche, Penzberg, Germany 
Chloroform  Roth, Karlsruhe, Germany  
Coomassie®Brillant Blue R-250  Sigma-Aldrich, Taufkirchen, Germany  
Connective tissue growth factor Self purification  
Connective tissue growth factor Prospec, Rehovot, Israel 
Decorin, human recombinant  R&D Systems, Minneapolis, USA 
Decorin, mouse recombinant  R&D Systems, Minneapolis, USA 
Desoxynukleosid-Triphosphate (dNTPs)  Qiagen, Hilden, Germany  
Dexamethason  Sigma-Aldrich, Taufkirchen, Germany  
Dimethylsulfoxid (DMSO)  Roth, Karlsruhe, Germany  
DL-Dithiothreitol (DTT)  Sigma-Aldrich, Taufkirchen, Germany 
Dulbecco's Modified Eagle Medium (DMEM)  PAA The Cell Culture Company, Pasching, 
Austria  
Dulbecco’s Modified Eagle Medium (DMEM) 
F12  
PAA The Cell Culture Company, Pasching, 
Austria 
Donkey Serum  Abcam, Cambridge, England  
EDTA Roth, Karlsruhe, Germany 
Epon  Serva, Heidelberg, Germany  
Ethanol 100%  Roth, Karlsruhe, Germany  
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Ethidiumbromide Serva, Heidelberg, Germany 
Fetal calve serum (FCS)  Biochrom AG, Berlin, Germany  
Fluorescein  Qiagen, Hilden, Germany  
Fluorescent Mounting Medium  DakoCytomation, Hamburg, Germany  
Formaldehyde Roth, Karlsruhe, Germany  
Gelatine Sigma-Aldrich, Taufkirchen, Germany 
Glutaraldehyde, 25% in water Serva, Heidelberg, Germany 
Glycerine  Roth, Karlsruhe, Germany  
Glycin  Merck, Darmstadt, Germany  
Guanidin HCl  Roth, Karlsruhe, Germany  
Hydrochloric acid (37%) Merck, Darmstadt, Germany 
Isoflurane Baxter, Heidelberg, Germany 
Isopropanol  Roth, Karlsruhe, Germany  
Ketamine  Wirtschaftsgenossenschaft Deutscher 
Tierärzte (WDT), Garbsen, Germany  
Luminata Forte, Western HRP Millipore Cooperation, Billerica, USA 
Magnesium chloride (25 mM)  Qiagen, Hilden, Germany  
Methanol  Merck, Darmstadt, Germany  
Milk powder (MM)  Roth, Karlsruhe, Germany   
MTT Reagent Roche, Mannheim, Germany 
N,N,N`,N`,-Tetramethylethylendiamine, 
(TEMED)  
Roth, Karlsruhe, Germany  
Paraformaldehyde (PFA)  Sigma-Aldrich, Taufkirchen, Germany  
PBS  PAA The Cell Culture Company, Pasching, 
Austria  
Penicilllin-Streptomycin  PAA The Cell Culture Company, Pasching, 
Austria  
Phalloidin  Sigma-Aldrich, Taufkirchen, Germany  
Phosphatase-Inhibitor-Mix Sigma-Aldrich, Taufkirchen, Germany 
Potassium chloride  Roth, Karlsruhe, Germany 
Potassium dihydrogen phosphate Roth, Karlsruhe, Germany 
Protease-Inhibitor-Mix M Serva Electrophoresis GmbH, Heidelberg, 
Germany  
Proteinase K Sigma-Aldrich, Taufkirchen, Germany 
peqGold TriFastTM (Trizol)  PeqLab, Erlangen, Germany  
Roti®-Free Strippingbuffer Sigma-Aldrich, Taufkirchen, Germany 
Rotiphorese® Gel 30 (30 % Acrylamid,   
0.8 % Bisacrylamid; 37.5:1)  
Sigma-Aldrich, Taufkirchen, Germany  
Saccharose Roth, Karlsruhe, Germany 
Sodium chloride Roth, Karlsruhe, Germany 
SDS (Sodium dodecylsulfat) Roth, Karlsruhe, Germany 
Sodium dihydrogen phosphate Merck, Darmstadt, Germany 
Sodium hydroxide Roth, Karlsruhe, Germany 
Sodium phosphate  Roth, Karlsruhe, Germany 
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SYBR-Green I  Qiagen, Hilden  
Tissue-Tek®  Sakura, Zoeterwoude, Netherlands  
Transforming Growth Factor 2 (TGFβ2)  R&D Systems, Minneapolis, USA 
Triciribine  Selleckchem, Houston, USA 
Tris Ultrapure, MB Grade Usb Coorporation, Cleveland, USA 
Tris HCl Roth, Karlsruhe, Germany 
Triton X 100 Roth, Karlsruhe, Germany 
Tween 20  Roth, Karlsruhe, Germany 
Vectashield Mounting Medium for      
Fluorescence with DAPI  
Vector Laboratories, Burlingame, USA  
Water Rotisolv (Rnase-free)  Roth, Karlsruhe, Germany 
Xylazine  Serumwerk Bernburg, Bernburg, Germany  
Table 1 : Reagents 
 
3.1.2 Enzymes and Reagent-Kits  
 
Designation Source of supply 
iScript™ cDNA Synthesis Kit  BioRad, Munic, Germany 
Hot Star Taq DNA Polymerase  Qiagen, Hilden, Germany  
qScript™ cDNA Synthesis Kit Quanta, Gaithersburg, USA 
Taq DNA Polymerase Self purification  
Table 2: Enzymes and reagent kits 
 
3.1.3 Oligonucleotide primers and DNA ladders 
 
Primer  Species Orientation Sequence 5' to 3'  
DCN 3 Mus musculus forward ctgaagatgacactggcatcgg 
DCN 5  Mus musculus reverse ccttctggcacaagtctcttgg 
DCN PGK Mus musculus forward tggatgtggaatgtgtgcgagg 
βB1 f Mus musculus forward gtgcgggacagaaacctg 
βB1 r Mus musculus reverse ggaagtgccagctcatcagt 
SV40 f Mus musculus forward gcgaaggaaccttacttctgtggtg 
SV40 r  Mus musculus reverse gtccttggggtcttctacctttctc 
Table 3: Primers for Genotyping PCR   
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Primer  Species  Orientation  Sequence 5' 
to 3'  
Position  
Col IV a2 Homo sapiens forward acaggacagaaa
ggagacca 
1307 - 1326 
Col IV a2 Homo sapiens reverse ggtgtgatgcctgg
gaac 
1381 - 1400 
CTGF  Homo sapiens  forward  ctcctgcaggctag
agaagc  
884 - 903  
CTGF  Homo sapiens  reverse  gatgcactttttgcc
cttctt  
957 - 977  
DCN   Homo sapiens forward tcgagtggtccagt
gttctg 
280 - 299 
DCN  Homo sapiens reverse cctttttggtgttgtgt
cca 
365 - 384 
FN  Homo sapiens  forward  ccctgattggaagg
aaaaaga  
6217-6237  
FN  Homo sapiens  reverse  atgaagattggggt
gtggaa  
6265-6284  
GNB2L* Homo sapiens forward gctactaccccgca
gttcc 
170 - 188 
GNB2L* Homo sapiens reverse cagtttccacatgat
gatggtc 
220 – 241 
TGF β 1 Homo sapiens forward cagccggttgctga
ggta 
1362 – 1379 
TGF β 1 Homo sapiens reverse aagaagcgggcttt
ggac 
1408 – 1425 
TGF β 2 Homo sapiens forward ccaaagggtacaa
tgccaac 
1194 – 1213 
TGF β 2 Homo sapiens reverse cagatgcttctggat
ttatggtatt 
1283 – 1307 
CTGF  Mus musculus  forward  tgacctggaggaa
aacattaaga  
948-970  
CTGF  Mus musculus  reverse  agccctgtatgtctt
cacactg  
1038-1059  
DCN Mus musculus forward gagggaactccac
ttggaca 
1039-1058 
DCN  Mus musculus reverse ttgttgttgtgaaggt
agacgac 
1134-1112 
GNB2L* Mus musculus  forward  tctgcaagtacacg
gtccag  
514 – 533  
GNB2L* Mus musculus  reverse  gagacgatgatag
ggttgctg  
584 – 604  
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FN Mus musculus forward cggagagagtgcc
cctacta 
4201 – 4220 
FN Mus musculus reverse cgatattggtgaatc
gcaga 
4277 – 4258 
GFAP Mus musculus forward tcgagatcgccacc
tacag 
1156 – 1174 
GFAP Mus musculus reverse gtctgtacaggaat
ggtgatgc 
1201 – 1222 
RPL32* Mus musculus forward gctgccatctgtttta
cgg 
29-47 
RPL32* Mus musculus reverse tgactggtgcctgat
gaact 
107-126 
TGF β 1 Mus musculus forward tggagcaacatgtg
gaactc 
1358 – 1377 
TGF β 1 Mus musculus reverse gtcagcagccggtt
acca 
1413 – 1430 
TGF β 2 Mus musculus forward tcttccgcttgcaaa
acc 
4795 - 4812  
TGF β 2 Mus musculus reverse gtgggagatgttaa
gtctttgga 
4863 - 4885 
αSMA Mus musculus forward caaccgggagaa
aatgacc 
667 - 685 
αSMA Mus musculus reverse cagttgtacgtcca
gaggcata 
752 - 773 
Table 4: Primers for Real Time RT PCR; * housekeeper   
 
All primers were purchased from Invitrogen, Karlsruhe, Germany. 
 
3.1.4 Antibodies and molecular weight standards  
 
Protein  Primary antibody  Source of supply   
AKT  Monoclonal rabbit anti 
human/mouse/rat AKT 
Cell Signaling Technology, 
Cambridge, England 
CTGF  Polyclonal goat anti 
human/rat CTGF  
Santa Cruz Biotechnology, 
Santa Cruz, USA  
Collagen-Typ-IV  Polyclonal rabbit anti human 
Collagen Type IV  
RDI, Flanders, NJ, USA  
Decorin LF136 Polyclonal rabbit anti human 
DCN 
L. Fisher 
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Decorin LF113 Polyclonal rabbit anti mouse 
DCN 
L. Fisher 
Decorin H80 Polyclonal rabbit anti 
human/mouse DCN 
Santa Cruz Biotechnology, 
Santa Cruz, USA 
Fibronectin Polyclonal rabbit anti 
Fibronectin 
Dako, Hamburg, Germany 
Fibronectin H300 Polyclonal rabbit anti human 
Fibronectin  
Santa Cruz Biotechnology, 
Santa Cruz, USA 
GFAP Polyclonal 
chicken-anti-GFAP 
Lifespan, Biosciences, 
Seattle, USA 
GFAP Polyclonal rabbit anti GFAP Dako, Hamburg, 
Deutschland 
Phospho AKT Monoclonal rabbit anti 
human/mouse/rat pAKT 
Cell Signaling Technology, 
Cambridge, England 
 
Phopspho Smad2 Monoclonal rabbit anti 
human/mouse/rat pSmad2 
Cell Signaling Technology, 
Cambridge, England 
Smooth-muscle  
α-Actin  
Monoclonal mouse anti 
Mouse  
Immunotech International 
(Dianova), Hamburg  
Tubulin α Polyclonal rabbit anti human Rockland, Pottstown, USA 
Table 5: Primary antibodies 
 
Secondary antibody  Source of supply  
AffiniPure Donkey Anti Rabbit Cy™3 
conjugated 
Dianova, Hamburg, Germany  
AffiniPure Donkey Anti Goat Cy™3 
conjugated  
Dianova, Hamburg, Germany  
Chicken anti Goat IgG, AP conjugated  Santa Cruz Biotechnology, Santa Cruz, 
USA  
Chicken anti Goat IgG, HRP conjugated Santa Cruz Biotechnology, Santa Cruz, 
USA 
Chicken anti Rabbit IgG, AP conjugated  Santa Cruz Biotechnology, Santa Cruz, 
USA  
Chicken anti Rabbit IgG, HRP conjugated  Santa Cruz Biotechnology, Santa Cruz, 
USA  
Chicken anti Rabbit IgG, AP conjugated Cell Signaling Technology, Cambridge, 
England  
Chicken anti Rabbit IgG, HRP conjugated Cell Signaling Technology, Cambridge, 
England  
Rabbit anti GPADH, HRP conjugated Cell Signaling Technology, Cambridge, 
England 
Streptavidin Alexa Fluor® 488 conjugated  MoBitec Molecular Probes, Goettingen  
Table 6: Secondary antibodies 
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Tables above show all antibodies used for western blotting and immunohistochemistry. 
In western blot analysis the height of detected bands was determined with a protein 
molecular weight standard (Fisher BioReagentsTM EZ-RunTM Prestained Rec Protein 
Ladder, Fisher Scientific, Waltham, USA).  
 
3.1.5 Chemical composition of gels, solvents and buffers  
 
Solvent/Buffer  Composition  
0.1 M Cacodylate Buffer   
 
10.7 g Cacodylate acid in 500 ml dH2O 
0.1 M Phosphate Buffer, pH 7.4  100 ml 0.2 M Na2HPO4 x 2H2O  
with 0.2 M NaH2PO4 x H2O, pH 7.4  
dilute with dH2O to 0.1 M  
10 x Electrode Buffer  250 mM Tris/HCl  
400 mM Glycin  
1% (w/v) SDS solved in dH2O; ad 1 l  
Coomassie-Destaining Solution  500 ml Methanol  
10 ml Actic acid   
filled up with ad 1 l  
Coomassie-Staining Solution 40 ml Methanol  
2 ml Acetic acid  
0.2 g Coomassie-Brilliant Blue R-250  
filled up with; ad 100 ml  
Detection Buffer, pH 9  15.76 g 0.1 M Tris/HCL (pH 6.8)  
5.84 g 0.1 M NaCl  
solved in dH2O; ad 1 l  
Epon Stem A  62 ml Glycidether 100 with 100 ml DDSA 
Epon Stem B 100 ml Glycidether 100 with 89 ml NMA 
Mowiol with DAPI  2.4 g Mowiol 4-88 
6.0 g Glycerin 
6.0 ml H2O dest. 
12.0 ml 0.2 M Tris-HCl (pH 8.5) 
25.0 ml DABCO per 1.0 ml  
DAPI (1:10) 
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PBS, 10x, pH 7.4  80 g NaCl  
2 g KCl  
4.4 g Na2HPO4  
2.4 g KH2PO4  
dH2O ad 1 l, autoclave  
RIPA-Buffer, pH 8  150 NaCl  
1 % ( v/v ) Tergitol  
0.5 % ( w/v ) Deoxycholic acid  
0.1 % ( w/v ) SDS  
50 mM Tris  
SDS 10 % (w/v)  10 g SDS  
in dH2O; ad 100 ml  
SDS-PAGE-Running Buffer, 10x  250 mM Tris/HCl  
400 mM Glycin  
1% (w/v) SDS  
in dH2O; ad 1 l  
SDS-Sample Buffer, 5x  0.25 M Tris/HCl, pH 6.8  
30 % Glycerin  
8 % (w/v) SDS  
0.02 % (w/v) Bromophenol blue  
0.3 M DTT and 10% β-Mercaptoethanol  
TBS 10x, pH 7,4  30 g Tris  
80 g NaCl 
2 g KCl  
dH2O ad 1 l, autoclave  
TBST 1x  100 ml 10x TBS  
0.05% (v/v) Tween 20  
dH2O ad 1 l  
Transfer Buffer 10x  5.8 g Tris  
2.9 g Glycin  
200 ml Methanol  
3.7 ml 10% (w/v) SDS  
in dH2O, ad 1 l  
Tris/HCl, 1.0 M, pH 6.8  121.14 g Tris  
in dH2O; ad 1 l  
Tris/HCl, 1.5 M, pH 8.8  181.71 g Tris  
in dH2O, ad 1 l  
Washing Buffer for protein isolation  0.3 M Guanidine HCL  
in 95 % Ethanol  
Table 7: Composition of solvents and buffers 
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3.1.6 Laboratory Equipment  
 
Designation  Source of supply  
Axiovert 40 CFL  Zeiss, Göttingen, Germany   
BioPhotometer  Eppendorf, Hamburg, Germany  
Casy®  Innovatis, Reutlingen, Germany  
CFX Connect Real-Time PCR 
detection system  
BioRad, Munic, Germany 
Embedder EM TP Leica, Wetzlar, Germany  
FastPrep 24TM  MP Biomedicals, Burlingame, USA 
Hera Cell 150 Incubator Heraeus, Hanau, Germany  
Hera Safe steril work bench  Heraeus, Hanau, Germany  
Inolab pH-Meter  WTW GmbH, Weilheim, Germany  
IQ5 Multicolor Real-time PCR 
Detection System + iCycler  
BioRad, Munic, Germany 
Julabo SW20 water bath  Julabo Labortechnik GmbH, Seelbach, Germany  
Kern PJL 2100-2M analytical 
balance  
Kern & Sohn GmbH, Balingen-Frommern, Germany  
LAS 3000 Intelligent Dark Box  Fujifilm, Düsseldorf, Germany  
Mastercycler gradient, personal  Eppendorf, Hamburg, Germany  
Memmert water bath  Memmert GmbH, Schwabach, Germany  
Mettler AE 163 special accuracy 
scales  
Mettler Toledo, Giessen, Germany  
Microm HM 500 OM Kryostat  Microm International, Walldorf, Germany  
Mikroskop Axio Imager. Z1  Zeiss, Göttingen, Germany  
MilliQ Plus PF water purification 
system  
Millipore Corporation, Billerica, USA  
Minifold I Dot-Blot System SRC 
96 Acryl 
Schleicher & Schuell, Dassel, Germany  
Model 45-101-i ClassII 
Electrophoresis System  
Peqlab Biotechnologie GmbH, Erlangen, Germany  
NanoDrop-1000 
Spectrophotometer  
Peqlab Biotechnologie GmbH, Erlangen, Germany  
Pipetman Pipets  Gilson, Middleton, USA  
Polymax 1040 shaker  Heidolph, Kelheim, Germany  
PowerShot G5 Digital Camera  Canon, Krefeld, Germany  
Research Pipets  Eppendorf, Hamburg, Germany  
Semi-Dry Electrophoretic 
Transfer Cell  
Peqlab Biotechnologie GmbH, Erlangen, Germany  
Sunrise-Basic ELISA-Reader  Tecan Austria GmbH, Grodig, Austria  
Systec V75 Autoclave Systec GmbH, Wettenburg, Germany  
Thermal mixer comfort  Eppendorf, Hamburg, Germany  
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TonoLab Tonometer  Icare Finnland, Helsinki, Finnland  
UV-light screen Bachhofer Laboratoriumsgeräte, Reutlingen, 
Germany  
Ultracut E-Ultramicrotom Reichert-Jung, Kirchseeon, Germany 
Ultra Thurax Biolabproducts, Bebensee, Germany 
Vortex Genie 2  Scientific Industries Inc., New York, USA  
Centrifuges 5415D, 5415R, 
5804R, 5810R  
Eppendorf, Hamburg, Germany  
Table 8: Laboratory equipment 
 
3.1.7 Consumables  
 
Designation  Source of supply 
„Falcon“ Reaction Tubes 15 ml, 50 ml  Sarstedt, Nürnbrecht, Germany  
3MM Blotting ("Whatman") -Paper  Neolab, Heidelberg, Germany  
Biosphere Filter Tips  Sarstedt, Nürnbrecht, Germany  
CellScraper  Sarstedt, Nürnbrecht, Germany  
Culture Slides  BD Falcon, Bedford, USA  
Cover slips, 24 x 60mm  Menzel-Gläser, Braunschweig, Germany  
Dispomed Syringe, single use  Dispomed Witt oHG, Geinhausen, Germany  
EasyFlasks Nunclon™ Δ T25, T75  Nunc, Roskilde, Denmark 
Ecoflo Dissecting instruments Dispomed Witt oHG, Geinhausen, Germany  
Glassware  Schott, Roth, VWR, Germany 
Liquid Blocker PAP-Pen  SCI Science Services, Munic, Germany 
Lysing Matrix D MP Biomedicals, Burlingame, USA 
Microseal®„B“ Film  Biorad, Munic, Germany 
Multidishes Nunclon™ Δ 6-well  Nunc, Roskilde, Denmark  
Multi-Reactiontubes  Roth, Karlsruhe, Germany  
Omnifix syringe, sterile  B. Braun, Wertheim, Germany  
Parafilm  Pechiney Plastic Packaging, Chicago, USA  
Pasteurpipets  Brand, Wertheim, Germany  
PCR Plates, 96 well iCycler IQ  Biorad, Munic, Germany 
Personna Razor blades  American Safety Razor Company, Verona,USA  
Pipet tips   Sarstedt, Nürnbrecht, Germany  
Powderfree Sempercare gloves  Sempermed, Wien, Austria 
PVDF-Western Blot Membrane  Roche, Mannheim, Germany  
Rotilabo 0,22 μm syringe filter  Roth, Karlsruhe, Germany  
Serological pipets   Sarstedt, Nürnbrecht, Germany  
Sterican injection cannula  B. Braun, Wertheim, Germany   
SuperFrost®Plus object slides  Menzel-Gläser, Braunschweig, Germany  
Table 9: Consumables 
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3.2 Animal models  
 
3.2.1 Animals and animal husbandry 
 
For in vivo experiments CD1 wildtype mice, transgenic βB1-CTGF mice in a CD1 
background and DCN knockout (DCN -/-) mice in a mixed background were used.CD1 
mice were offspring of a breeding pair purchased at Charles River, Sulzfeld, Germany, 
and were bred in the animal facility of Prof. Dr. E. Tamm, institute for human anatomy 
and embryologie, University of Regensburg. Transgenic βB1-CTGF mice have been 
generated in our own working group and were kindly provided by Prof. Dr. R. Fuchshofer 
(Junglas et al., 2012). DCN -/- mice have been generated in the group of Prof. Dr. R. 
Iozzo at the institute for pathology and cell biology, Thomas Jefferson University, USA 
(Danielson et al., 1997). These mice were kindly provided by Prof. Dr. L. Schaefer 
(Pharma Zentrum Frankfurt, Goethe University, Germany). 
All animals were kept accordingly to the ARVO Statement for the use of animals in 
ophthalmic and vision research, at temperatures of 23 ± 2 °C and humidity of 55 ± 5 %, 
with food and water ad libitum. Light-dark circles were set to 12 hours.   
 
3.2.2 βB1-CTGF mice  
 
Transgenic βB1-CTGF mice carry a construct in which murine CTGF cDNA is controlled 
via the chicken- βB1 promotor. This leads to a lens specific overexpression of CTGF. 
Additionally a SV40 poly(A) sequence of the SV40 small T-intron is located at the end of 
the construct. Thereby the polyadenylation signal is transcribed to ensure the stability of 
CTGF mRNA. To be able to analyze wildtype littermates, a CD1 Wildtype (WT) animal 
was mated with a transgenic animal. Genotyping of the animals was carried out as 
described in 3.2.2.1.  
 
 
 
Figure 7: βB1 construct of βB1-CTGF mice  (Provided by Prof. Dr. R. Fuchshofer, modified)  
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3.2.3 DCN Knockout (DCN-/-) mice 
 
In this mouse line the function of DCN is destroyed by integration of a neomycin 
resistance cassette under the control of the Pgk promotor. This leads to a systemic 
knockout of DCN (Danielson et al., 1997). To be able to use wildtype littermates as 
control groups, heterozygous DCN+/- animals were mated, resulting in homozygous 
knockout, homozygous wildtype and heterozygous offspring.  
 
3.3 Biomolecular Techniques  
 
3.3.1 Isolation of mouse tail DNA  
 
For genotyping genomic mouse tail DNA was used. Mice were anesthetized with 
Isoflurane and about 0.5 cm of the tail was cut off, using sterile surgical scissors. The 
mouse tail was transferred to a 1.5 ml tube and lysed with 200 µl proteinase K lysis 
buffer for at least 12 h at 55 °C. After this proteinase K was inactivated for 10 min at 95° 
C. Samples were centrifuged for 10 min at 10000 rpm to sediment insoluble parts. 
Genotyping PCRs were carried out with specific primers as described in 3.3.2. 
  
3.3.2 Genotyping 
 
Genotypes of the analyzed mice were determined by PCR (polymerase chain reaction) 
using specific primers (Table 3). Reaction mixes are shown in tables 10, 11 and 13. 
After amplification of the targeted sequence (Cycler Programs see table 12 and 14) the 
samples were loaded on agarose gels for electrophoreses. 
 
3.3.2.1 Genotyping of βB1-CTGF mice 
 
Genotyping of βB1-CTGF mice was carried out with specific primers for the βB1- and 
the SV40 region (Table 3), which are both expressed in transgenic animals only. 
Reaction mixes for PCRs are shown in table 10 and 11. 
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βB1 PCR 
H2O 11.25 µl 
Q-Buffer 1.5 µl 
βB1 Primer forward 1:10 0.3 µl 
βB1 Primer reverse 1:10 0.3 µl 
dNTPs (10mM) 0.3 µl 
Taq DNA-Polymerase 0.15 µl 
DNA 1.2 µl 
Table 10: Reaction mix for βB1 PCR 
 
SV40 PCR 
H2O 7.35 µl 
Q-Buffer 1.5 µl 
5x Glycerol 3 µl 
SV40 Primer forward (1:10) 0.3 µl 
SV40 Primer reverse (1:10) 0.3 µl 
dNTPs (10mM) 0.3 µl 
MgCl2 (25mM) 1 µl 
Taq DNA-Polymerase 0.25 µl 
DNA 1 µl 
Table 11: Reaction mix for SV40 PCR  
 
βB1 and SV40 PCR Cycler Programs  
Product βB1 SV40 
360 bp 300 bp 
° C Duration ° C Duration 
1. Step 96 2 min 94 2 min 
2. Step 90 30 sec 94 30 sec 
3. Step 65 30 sec 55 30 sec 
4. Step 72 20 sec 72 45 sec 
5. Step 72 2 min 72 5 min 
6. Step 10 ∞ 10 ∞ 
Cycles (2-5) 35 x 35 x 
Table 12: Thermocycler programs for βB1- and SV40 PCR  
 
3.3.2.2 Genotyping of DCN-/- mice  
 
For genotyping of DCN-/- mice three different primers were used: one forward primer 
binding specifically in exon 2 (DCN3), one forward primer binding specifically to the pgk 
neomycin cassette (PGK Neo) and one reverse primer binding specifically to exon 2 
(DCN 5). By using all three primers, wildtype-, knockout- and heterozygous animals can 
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be identified in the same PCR. The PCR results in a 161 bp product for wildtype- and in 
a 250 bp product for knockout animals. Heterozygous animals show both products.  
 
DCN PCR 
H2O 22 µl 
Q-Buffer 5 µl 
DCN 3 (1:10) 1 µl  
PGK Neo (1:10) 1 µl 
DCN 5 (1:10) 1 µl 
dNTPs (10mM) 1 µl 
Taq DNA-Polymerase 1 µl 
DNA 3 µl 
Table 13: Reaction mix for DCN PCR 
 
DCN PCR Cycler Program 
Product  DCN WT DCN -/- 
161bp 250 
° C Duration 
1. Step 95 4 min 
2. Step 95 30 sec 
3. Step 58 30 sec 
4. Step 72 30 sec 
5. Step 72 2 min 
6. Step 10 ∞ 
Cycles (2-5) 35 
Table 14: Thermocycler programs DCN PCR  
 
3.3.3 Agarose gel electrophoresis 
 
Agarose gel electrophoresis was used to analyze the DNA products of genotyping 
PCRs. 2 mg of agarose were dissolved in 100 ml TBE Buffer. Afterwards 4 µl of 
ethidium bromide (EtBr) at a final concentration of 50 ng/ml were added. EtBr 
intercalates in double stranded DNA and thereby makes the DNA fragments visible 
under UV light. 10 µl of the PCR product including loading dye were loaded on the 
agarose gel and then separated for 30 min at 130 V. To determine the size of the PCR 
product 2 µl of a standard DNA marker were loaded on the gel. DNA fragments were 
made visible using UV light (302 nm).   
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3.4 Expression analysis 
 
3.4.1 RNA isolation  
 
RNA from human and murine cells, as well as of mouse tissue was isolated after 
Chomczynski and Sacchi (Chomczynski and Sacchi, 1987). To decompose the cells and 
dilute the cell components peqGold TriFastTM Trizol reagent was used (Peqlab 
Biotechnologie GmbH, Erlangen). This single phase solution is based on phenol and 
guanidinisothiocyanat, and can be divided into three phases by the addition of 
chloroform. These phases contain RNA (aqueous phase), DNA (interphase) and 
proteins (phenol phase).  
Samples for Real Time PCR were assimilated using an Ultra Thurax (Biolabproducts, 
Bebensee, Germany) in 500 µl of pegGold TriFastTM Trizol. 
Samples for RNA sequencing were kept in 800µl RNA Later till further use. They were 
then transferred in 800µl pegGold TriFastTM Trizol in Shredder Tubes (Lysing Matrix D, 
MP Biomedicals, Burlingame, USA) and shredded for 45 sec and 6 m/s in a  
FastPrep-24TM instrument (MP Biomedicals, Burlingame USA). Afterwards Shredder 
Tubes were centrifuged for 2 min at 13000 rpm and the supernatant was transferred into 
a fresh reaction tube and 200µl pegGold TriFastTM were added. 
After 5 min 140 µl per 500 µl pegGold TriFastTM Chloroform were added. After shaking 
thoroughly samples were incubated on ice for 5 min. Separation of phases was then 
achieved by centrifugation (20 min, 4 °C, 13200 rpm). The aqueous phase then was 
transferred carefully, without any components of the inter- or phenol phase, into a new 
tube and 300 µl of isopropanol were added. For precipitation of the RNA the samples 
were stored over night at -20 °C. Afterwards samples were centrifuged for 20 min (4 °C, 
13200 rpm) to pelletize the RNA. The supernatant was discarded and the RNA pellet 
was washed twice in 1 ml 75% ethanol for 5 min and then centrifuged for 5 min (4 °C, 
7600 rpm). After quantitative removal of the supernatant and drying of the RNA pellet, it 
was dissolved in 10 µl of RNase-free water. RNA was stored at -80 °C till further use.  
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3.4.2 RNA quantification 
 
RNA was quantified using a NanoDrop-2000c spectral photometer (Peqlab 
Biotechnologie GmbH, Erlangen). The optical density of the sample was measured at  
λ = 260 nm (OD260), which is the absorption peak of nucleic acids (DNA, RNA), and at 
λ = 280 nm (OD280), which is the absorption peak of proteins against the solvent (H2O).  
A OD260 of 1 is consistent with a RNA concentration of 40 µg/ml, therefore the 
concentration of RNA can be calculated as follows: 
 
[μg/ml] = OD260 × 40 μg/ml 
 
Purity of RNA can be determined via the OD260 to OD280 ratio. Pure RNA should have 
a ration between 1.7 and 2.0.  
 
3.4.3 cDNA production  
 
To analyze relative gene expression via real time RT PCR, RNA has to be transcribed to 
cDNA via reverse transcription. Oligo-dt-chains were used as primer to ensure that 
mRNA with polyA tail was transcribed. For cDNA synthesis “qScriptTM cDNA Synthesis 
Kit” was used (Qanta Biosciences, Gaithersburg, USA). 200 ng or 500 ng of RNA were 
diluted in H2O to a volume of 7.5 µl and then 2.0 µl of qScriptTM Reaction Mix and 0.5µl 
of qScriptTM reverse Transcriptase were added. For each cDNA synthesis at least 3 
negative controls (-RT), containing no reverse transcriptase, were made in addition to 
the cDNA samples (+RT). –RTs are necessary to estimate possible contamination of 
RNA. CDNA synthesis was carried out in a Thermocycler (Biorad, Munic, GER) using 
the following program 
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Program for cDNA synthesis 
Step 1 Incubation for  5min at 22°C 
Step 2 Reverse transcription for 30min at 42°C 
Step 3 Inactivation of reverse Transcriptase for  
5min at 85°C 
Table 15: Program for cDNA synthesis  
 
3.4.4 Procedure of quantitative Real Time RT PCR 
 
Relative gene expression of TGFβ1, TGFβ2, CTGF, FN and Col IV was analyzed in the 
corneo-scleral ring, in the optic nerve and in the optic nerve head of 8 week old DCN WT 
and DCN-/- mice. DCN expression was analyzed in the corneo-scleral ring, the optic 
nerve and the optic nerve head of 8 week old βB1-CTGF mice.  
Human trabecular meshwork cells and optic nerve head astrocytes as well as murine 
optic nerve astrocytes were analyzed regarding their expression of DCN after treatment 
with either TGFβ2 or CTGF, and regarding their expression of TGFβ1, TGFβ2, CTGF, 
FN and Col IV after treatment with DCN. Murine optic nerve astrocytes were further 
analyzed regarding their expression of TGFβ1, TGFβ2, CTGF and DCN after treatments 
with DCN and the AKT-Signaling inhibitor triciribine.  
Real Time PCR was carried out with an iQ5TM Multicolor Real-Time-PCR Detection 
System with iCycler or with a CFX ConnectTM Real-Time PCR detection system 
(BioRad, Munic, GER). PCR products were detected via SYBR-Green I. Probes can be 
relatively standardized via the use of housekeeping genes. Used housekeeping genes 
are listed in Table 3.4. Each cDNA sample (+RT) was analyzed as a triplicate. To 
exclude possible contamination negative controls (-RT) and non-template controls (NTC) 
containing RNase free water were included. Each +RT, -RT and NTC was filled up with 
a Master-Mix (see Table 3.3.7) to a total volume of 10 µl. Samples were pipetted onto a 
96-Well-Microtiterplate and 5 µl of Primer-Mix (0.17 µl forward primer, 0.17 µl reverse 
primer (0.1 M) and 4.66 µl RNase free water) with specific primers for the gene of 
interest were added.   
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Master-Mix (one reaction) 
0.3 μl sample (+RT cDNA, -RT cDNA or RNase free water) 
2.0  μl 10x PCR Buffer 
0.8  μl MgCl2 (25mM) 
0.16  μl dNTPs 
0.08  μl Taq DNA Polymerase (5 U/μl) 
0.25  μl SYBR-Green I (7.4 % (v/v) in DMSO) 
0.02  μl Fluorescein 
0.17  μl per Primer (1μM) 
11.49  μl RNase-free water 
Table 16: Master Mix Real Time PCR  
 
Plates were sealed with adhesive foil (Microseal „B“Film, BioRad, Munic, GER) and 
centrifuged shortly. The Real Time PCR program was carried out as follows: 
 
Step Temperature Duration 
1 94°C 2min 
2 (50x) 94°C 
60°C 
70°C 
20s 
10s 
20s 
3 95°C 1min 
4 (81x) 55°C +0.5°C per cycle 6s 
5 4°C ∞ 
Table 17: Program for quantitative Real Time PCR  
 
To analyze relative expression the program CFX Manager 3.1 was used (BioRad, 
Munic, GER). Via the Ct (Cycle threshold) value, meaning the cycle in which 
fluorescence is higher than background fluorescence, relative gene expression can be 
calculated. Therefore lower Ct values represent higher expression levels. Melting curves 
conduce to check the specificity of the products after the run (Wong and Medrano, 
2005). Relative expression of target genes was calculated via the 2–ΔΔct method 
(Schmittgen and Livak, 2008). Data analysis and graphical representation was carried 
out using Microsoft® Excel (Microsoft ® Corporation, Redmond, USA). 
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3.4.5 RNA sequencing  
 
RNA Sequencing of corneo-scleral rings 8 and 12 week old DCN-/--  and βB1-CTGF 
mice and their wildtype litter mates was carried out by M. Kretz and C. Ziegler 
(University of Regensburg, Germany).  
 
3.5 Biochemical techniques  
 
3.5.1 Protein isolation  
 
3.5.1.1 RIPA-method 
 
Protein from huTM cells as well as human and murine Astrocytes was isolated with 
RIPA Buffer. Cells were incubated with 300 µl RIPA Buffer + Protease inhibitor (1:100) + 
Phosphatase inhibitor (1:100) on ice for 5 min. Cells were scraped of the culture dishes 
and the lysate was transferred into a reaction tube. After 30 min incubation on ice the 
lysate was centrifuged for 10min and 20000 rpm. The supernatant was transferred into a 
new reaction tube and kept at -80 °C till further use.  
 
3.5.1.2 peqGold TriFastTM Trizol-method  
 
Protein of human and murine cells and mouse tissue was isolated, after RNA isolation 
with peqGold TriFastTM Trizol-Reagent, from the inter- and phenol phase. Protein was 
precipitated with 750 µl Isopropanol per 500 µl peqGold TriFastTM Trizol. Previous 
steps for homogenization, separation of phases and RNA isolation are described in 3.3.1. 
Protein was precipitated for 10 min at RT and then pelletized by centrifugation (12000 g, 
10 min). Supernatant was discarded and the pellet was washed three times in 1 ml 
washing buffer (0.3 M guanidinhydrochloride in 95% EtOH) with 20 min incubation at RT 
and centrifugation for 5 min (7600 g, 4 °C). As a fourth washing step the protein pellet 
was incubated in 95% ETOH for 20 min. After centrifugation the supernatant was 
discarded completely and the pellet was dried for 5 min at RT. The pellet was dissolved 
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in 200 µl SDS + protease inhibitor + phosphatase inhibitor and incubated over night at 
50 °C. Insoluble components were sedimented by centrifugation for 10 min (10000 g, 
4 °C). The supernatant, containing the protein, was taken off and stored at -80 °C till 
further use.  
 
3.5.2 SDS-Polyacrylamide-gel electrophoresis  
 
For western blot analysis proteins were separated via gel electrophoresis. Productions 
of polyacrylamide gels and gel electrophoreses was carried out using the Laemmli 
method (Laemmli, 1970).  
 
Ingredient Stacking gel 
Running gel  
6% 
>130kDa 
12 % 
35 – 130kDa 
15 % 
< 35kDa 
dH2O 0.68 ml 2.6 ml 1.6 ml 1.1 ml 
Rotiphorese® Gel 30 0.17 ml 1.0 ml 2.0 ml 2. 5ml 
Tris/HCl, 1 M, pH 6,8 0.1 3ml - - - 
Tris/HCl, 1,5 M, pH 8,8 - 1.3 ml 1.3 ml 1.3 ml 
10% SDS 0.01 ml 0.05 ml 0.05 ml 0.05 ml 
10% APS 0.01 ml 0.05 ml 0.05 ml 0.05 ml 
TEMED 0.001 ml 0.004 ml 0.002 ml 0.002 ml 
Table 18: Components of SDS gels 
For pouring of gels a PeqLab Biotechnology GmbH upper buffer chamber and casting 
base were used. First the running gel was poured in between two glass slides and 
covered with 300 µl Isopropanol. After complete polymerization of the running gel, the 
stacking gel was poured on top of the running gel. A plastic comb was inserted in the 
liquid stacking gel to create loading wells.  
In the stacking gels protein samples can be concentrated due to the difference in pore 
size, pH and the electrophoretic mobility of ions to the running gel. In the running gels 
proteins are separated according to size. SDS in the gels ensures denaturation during 
the electrophoresis. Further proteins SDS ads negative charges to proteins 
corresponding to their molecular weight. This enables separation according to molecular 
weight in an electronic field.  
Previous to electrophoresis protein samples were denaturated with reducing sample 
buffer for 5 min in boiling water. Fully polymerized gels were transferred into an 
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electrophoresis chamber and the tank was filled with 1x running buffer. Samples were 
loaded in the loading wells and 5 µl of a protein molecular weight marker (Fisher 
Scientific, Waltham, USA) were loaded in an additional well.  
Proteins were separated at 20 mA per gel for 1 h 15 min. The stacking gel was 
discarded after electrophoresis.  
 
3.5.3 Semidry blotting 
 
Separated proteins were transferred on a polyvinylidene difluoride (PVDF) membrane 
(Roche, Mannheim, Germany) in a semidry blotting apparatus (Peqlab Biotechnology 
GmbH, Erlangen, Germany). The PVDF was cut to match the size of the running gel and 
shortly incubated in Methanol for activation. Afterwards the membrane was equilibrated 
in transfer buffer. Whatman papers were also soaked in transfer buffer. Blots were 
assembled as follows: 
 
Semidry Blot: 
Cathode (-) 
3 layers Whatman paper 
Running gel with proteins 
PVDF-Membrane 
2 layers Whatman paper 
Anode (+) 
Table 19: Semidry blotting 
 
Blotting was carried out at 14 V, 19 mA per gel for 45 min.   
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3.5.4 Dot blotting 
 
To analyze levels of secreted DCN in the media of murine astrocytes after treatments 
with TGFβ-2 or CTGF, medium was taken off the cells and stored at -80 °C till further 
use. Secreted protein was blotted on PVDF membranes via dot blotting. At first the 
membrane was activated in methanol and then equilibrated in transfer buffer. One layer 
of Whatman paper, soaked in transfer buffer was placed on the lower part of the Dot 
Blotter (Schleicher & Schuell, Dassel, Germany). The PVDF membrane was placed on 
top of the Whatman paper and the upper part of the Dot Blotter was placed onto the 
membrane. The Dot Blotter was connected to an aspirator hose to aspirate the medium 
through the membrane. 100 µl of medium were loaded per dot. After the medium was 
aspirated completely the membrane was washed in TBST shortly and then incubated in 
5% BSA for 1h at RT.  
3.5.5 Detection of specific protein bands  
 
To detect proteins of interest PVDF membranes were incubated with specific antibodies 
after blotting and blocking over night at 4 °C. As loading control α-Tubulin was used.  
Antibodies bind specifically to their fitting antigen and this so formed antibody-antigen 
complex can be bound by a secondary antibody against the host species of the primary 
antibody. Secondary antibodies are conjugated with horseradish peroxidase (HRP) or 
alkaline phosphatase (AP). If a HRP- or AP substrate is added to the antibody complex 
a catalysis reaction takes places in which chemiluminescence is emitted. This emission 
makes it possible to detect specific proteins.  
 
Primary antibody 
(dilution) 
Secondary antibody  
(dilution) 
Molecular weight Gel 
AKT (rabbit) 
1:1000 in 5% BSA 
α-rabbit-IgG-HRP (chicken) 
1:5000 
60 kDa 10% 
CTGF (goat) 
1:500 in 5% BSA 
α-goat-IgG-AP (chicken) 
1:2000 
37 kDa 
 
12% 
Col IV (rabbit) 
1:500 in 5% BSA 
α-rabbit-IgG-HRP (chicken) 
1:5000 
170 kDa 6% 
DCN (rabbit) LF 113 
1:500 in 5% BSA 
α-rabbit-IgG-HRP (chicken) 
1:5000 
40 kDa 12% 
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DCN (rabbit) H80 
1:200 in 5% MM 
α-rabbit IgG-AP (chicken) 
1:2000 
40 kDa 12% 
DCN (rabbit) LF 136 
1:100 in 5% BSA 
α-rabbit-IgG-HRP (chicken) 
1:5000 
40 kDa 12% 
Fibronectin 
1:500 in 5% MM 
α-rabbit IgG-AP (chicken) 
1:2000 
262 kDa 
 
6% 
GAPDH (rabbit) HRP 
1:5000 
- 39 kDa - 
pAKT (rabbit) 
1:1000 in 5% BSA 
α-rabbit-IgG-HRP (chicken) 
1:5000 
62 kDa 10% 
α-Tubulin (rabbit) 
1:5000  
α-rabbit IgG-AP (chicken) 
1:2000 
50 kDa 
 
- 
Table 20: Dilutions and specifications of primary antibodies 
 
After semidry- or dot blot membranes were incubated in 5% BSA or 5% MM for 1h at 
RT. Then the membranes were incubated over night at 4 °C with a primary antibody. 
After three washing steps in TBST (10min each) the secondary antibody was poured on 
the membrane. 1 h of incubation at RT was followed by three washing steps in TBST 
(10min each). At all steps the membrane was shaken gently in the solutions. All 
antibodies were diluted in 1:10 blocking solution in TBST. For detection of HRP 
conjugated antibodies 800µl LuminataTM Forte (Millipore, Billerica, USA) were dispersed 
on the membrane and the membrane was covered with foil and incubated in the dark for 
5 min. For detection of AP conjugated antibodies the membrane was incubated in 
detection buffer for 5min at RT and then 800 µl CDP Star (Roche, Penzberg, Germany) 
diluted 1:100 in detection buffer were used, following the same protocol as for HRP 
conjugated antibodies. Chemiluminescence signals were detected in a LAS3000 
Intelligent Dark Box (Fujifilm, Düsseldorf, Germany). Densitometric analysis was carried 
out with Aida Advanced Image Data Analyzer Version 4.06 (Raytest, Straubenhardt, 
Germany).   
 
3.5.6 Coomassie staining  
 
Proteins on the PVDF membranes were made visible with Coomassie staining 
(Sambrook et al., 1989). Staining was used as an additional loading control.  
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Membranes were incubated in coomassie staining solution for at least 1 h at RT. 
Afterwards the staining solution was discarded and the membranes were washed in 
destaining solution over night at RT. Membranes were dried completely and 
photographed in a LAS3000 Intelligent Dark Box (Fujifilm, Düsseldorf, Germany). 
Densitometric analysis was carried out with Aida Advanced Image Data Analyzer 
Version 4.06 (Raytest, Straubenhardt, Germany).   
 
3.6 Cell culture  
 
3.6.1 Cell lines and culture conditions  
 
Line Medium Temperatur/CO2 
human trabecular meshwork 
cells 
DMEM F12 + 5% (v/v) FCS,  
100 U/ml Penicillin, 100 µg/ml 
Streptomycin 
37 °C, 5% 
human astrocytes 
DMEM F12 + 10% (v/v) FCS, 
100 U/ml Penicillin, 100 µg/ml 
Streptomycin 
37 °C, 7% 
murine astrocytes 
DMEM F12 + 10% (v/v) FCS, 
100 U/ml Penicillin, 100 µg/ml 
Streptomycin  
37 °C, 7% 
Table 21: Culture conditions of used cell lines  
 
3.6.2 General working standards  
 
All treatments and other procedures were carried out under sterile conditions. Glassware 
was autoclaved prior to use; buffers and solutions were sterile filtered. Used plastic 
materials were packed sterile. Treatments and passaging as well as production of 
buffers and solutions were carried out under a sterile working bench (Hera Safe, 
Heraeus, Hanau, Germany). Cells were cultivated in an incubator (Hera Safe, Heraeus, 
Hanau, Germany) under sterile conditions with stable temperature, CO2 concentrations 
and an atmosphere saturated with water vapor.  
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3.6.2.1 Passaging of cells  
 
When cells reached confluency, they were detached from the bottom of the culture flask 
and sown diluted to a new culture flask. For treatments defined numbers of cells were 
sown in culture wells.  
At first culture medium was aspirated of the cells and cells were washed with sterile 
PBS. Then 1ml of Trypsin was added on the cell layer to detach cells from the culture 
flask. Cells were incubated with trypsin for about 5 min at 37 °C. Cells were detached 
from the culture flask by gently knocking on the flask.  
Trypsin was inactivated with 5 ml medium containing 10% FCS. To remove all trypsin of 
the cells, the cell suspension was centrifuged for 5 min at RT and 1000 rpm. The 
supernatant was discarded and the cell pellet was dissolved in 10 ml medium containing 
10% FCS.  
To passage cells 1ml of the cell suspension was added to a new culture flask containing 
an adjusted amount of medium containing 10% FCS.  
For treatment cells were counted with a Casy® (Innovatis, Reutlingen, Germany) and 
the desired number of cells was sown on culture wells.  
 
3.6.3 Isolation of murine optic nerve astrocytes  
 
For the isolation of murine optic nerve astrocytes 10 to 20 day old mice were used. After 
the mice were sacrificed, both eyes were enucleated using forceps. Till further dissection 
the eyes were stored shortly in cooled DMEM F12. ON were cut of the globes under a 
binocular and in a drop of DMEM F12 to prevent cells from drying. The dura was 
removed by gently sweeping over the optic nerve with forceps while one end of the ON 
was held in another forceps. On samples were digested in 200 µl Trypsin for 30 min at 
37°C. Tissue was then sheared by repeated pipetting and plated on laminin-coated 6 
well plates. Cells were grown in DMEM F12 enriched with 10% FCS and 1% AGS. 
Medium was not changed in the following seven days to allow the cells to attach to the 
tissue culture plates. After seven days, medium was changed three times a week. A 
pure astrocyte culture was obtained by shaking the wells for 12 h to remove less 
adhesive cells. After cells grew to confluence, they were seeded in 25 cm2 cell culture 
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flasks. Astrocytes were characterized via GFAP-staining. Only cells from passage 2 to 
10 were used for experiments.  
3.6.4 In vitro experiments  
 
Human TM cells, human astrocytes and murine astrocytes were sown on 6 well plates. 
When they reached confluency they were serum starved for 24 h. After 24 h medium 
was changed and proteins or inhibitors were added to the medium. At the end of the 
treatment medium was aspirated and the cells were washed twice in PBS. Cells were 
harvested after 30 min to 24 h accordant to the treatment. All treatments were carried 
out with at least three different charges of cells to ensure proper statistical analysis.  
 
3.6.4.1 Reciprocal effects of TGFβ-2, CTGF and DCN  
 
To analyze reciprocal effects of TGFβ-2 or CTGF and DCN human TM cells, human 
astrocytes and murine astrocytes were treated with 1 ng TGFβ-2, 50 ng CTGF, 25 ng 
CTGF or 1 µg DCN for 24 h. Untreated cells served as controls. After 24 h cells were 
harvested with 500 µl TrifastTM for isolation of RNA and proteins. Medium of treated cells 
was stored at -80 °C for quantification of secreted DCN, FN and Col IV.  
Further human TM cells, human astrocytes and murine astrocytes were sown on glass 
culture slides. After cells reached about 70% confluency they were serum starved for  
24 h and then treated as described above. After 24 h hours cells were washed twice with 
PBS and fixed in 4% PFA for 10 min. After three washing steps in 0.1 M phosphate 
buffer (30min each) culture slides were stored at -20 °C till further use. 
3.6.4.2 Effects of DCN on AKT signaling  
 
To investigate if DCN influences AKT signaling in murine astrocytes, the cells were 
treated with 1 µg of DCN for 30 min, 2 h, 3 h and 6 h, untreated cells served as controls. 
Cells were harvested in 300 µl RIPA buffer and lysates were stored at -80 °C till further 
use. 
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3.6.4.3. Inhibition of AKT signaling  
 
To reassess if DCN regulates expression of TGF-β1, TGF-β2 and CTGF via the the AKT 
signaling pathway (Figure 6) in murine astrocytes cells were treated with 1µg DCN only 
or in combination with the AKT signaling inhibitor Triciribine in different concentrations 
(0.5 µM, 1 µM, 5 µM) for 24 h. Cells were harvested in 500 µl TrifastTM.  
 
3.7 In vivo experiments  
 
3.7.1 Intraocular pressure measurements  
 
IOP was measured using a TonoLab tonometer (Icare, Tuike, Finnland). This tonometer 
is based on rebound tonometry. This means that the rebound force of the pin from the 
cornea is measured. The mean of 6 single measurements is taken and displayed in 
mmHg. 
Animals were anesthetized with 6 – 8 mg/kg bodyweight Xylazin and 90 – 120 mg/kg 
bodyweight Ketamine. First measurements were carried out 5 min after injection to 
ensure comparable depth of anesthesia. 
IOP measurements were either carried out before dissection or every 4 to 8 weeks for 
one year.  
3.7.2 Preparation of anterior eye segments and corneo-scleral rings 
 
Anterior eye segments or corneo-scleral rings of 8 and 12 week old DCN-/- and βB1 
CTGF mice and their wildtype littermates were dissected. Mice were killed by 
exarticulation of the atlanto-occipital joint after IOP measurements.  
The anterior eye segment was separated from the bulb by cutting along the ora serata 
and the lens was carefully taken out of the anterior eye segment. The anterior eye 
segment was transferred into 500 µl pegGold TrifastTM for isolation of RNA and proteins. 
To analyze regulation processes in the region of the TM without influences of corneal 
cells corneo scleral rims which include the TM were dissected. To do so the anterior eye 
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segment was cut in half after extraction of the lens. As much of the cornea as possible 
was cut of the corneo-scleral ring carefully.  
 
 
Figure 8: Dissection of the corneo-scleral ring.  Red lines indicate cuts. Blue = cornea, yellow = 
corneo-scleral ring, including TM. Samples were either processed immediately or stored at –80 °C till 
further use.  
 
3.7.3 Preparation of optic nerves and optic nerve heads  
 
Optic nerves and optic nerve heads of 8 and 12 weeks old DCN-/- and βB1-CTGF mice 
and their wildtype littermates were dissected.  
All muscles and connective tissue were cleaned away from the bulbus around the optic 
nerve. The optic nerve was cut off directly at the bulbus.  
To gain access to the optic nerve head, the anterior eye segment, the lens and the 
retina were removed. Then the sclera was incised three times all the way down to the 
optic nerve head, resulting in a four leave clover like shape. The four sclera parts were 
cut away from the optic nerve head and possibly remaining parts of sclera or retina were 
cleaned away.  
Optic nerves or optic nerve heads of two or three animals of the same genotype were 
paired in consideration of IOP values to get sufficient amounts of RNA and proteins. 
Samples were either processed immediately or stored at – 80°C till further use. 
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3.7.4 Transcardial perfusion  
 
Transcardial perfusion was used to fixate tissue for immunohistochemistry.  
Mice were anesthetized with Ketamine and Xylazine as described above. After animals 
showed no more pain reaction to pinching at the toes they were fixed to the working 
surface.  
An incision through the skin with surgical scissors was made along the thoracic midline 
and two additional incisions were made from the xiphoid process along the base of the 
ventral ribcage laterally. The thoracic field was exposed by reflecting the two skin flaps 
to the sides. The diaphragm was opened gently by raising the xiphoid process with blunt 
forceps and cutting it carefully with pointed scissors. Afterwards the thoracic 
musculature and the ribcage were cut on both sides close to the spine and they were 
fixed cranially with mosquito forceps placed on the xiphoid process. After removing the 
pericardial sac a perfusion cannula was inserted in the left ventricle right above the apex 
cordis and a small cut was made in the right atrium. Mice were perfused with about 5 ml 
of PBS till organs, especially the liver turned pale.  
Eyes were enucleated with bent forceps and placed in either 4% PFA for 4 h at RT (for 
immunohistochemistry) or in EM fixation for 24 h at 4 °C. After 1h a small incision was 
made in the cornea to ensure fixation of all structures of the eye.  
 
3.7.5 Quantification of optic nerve axons  
 
Differences in axon number between DCN-/- animals and wildtype littermates were 
analyzed using cross sections of optic nerves. The semi thin sections were stained with 
paraphenylenediamine and then pictures in 100x magnification were taken. The square 
footage of the optic nerve was measured with Axiovision 3.0. 
Axons were counted using Image J (RSB). Axons in five fields (50 x 50 µm each) were 
counted and then the whole number of axons was calculated using the following 
formula: 
Number of axons = (optic nerve (µm²) / 12500 µm²) · sum of axons in five fields 
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3.8 Histological techniques  
 
3.8.1 Cryo-embedding and sectioning  
 
After fixing eyes were washed three times in PBS for 30 min. For stabilization of the 
tissue eyes were incubated in rising concentrations of sucrose in phosphate buffer (10%, 
20%, 30%) for about 12 h per step. Eyes were embedded in Tissue-Tek® and stored at 
– 20 °C till further use. 12 µm sagittal or tangential cryo sections were made with a 
Microm HM500 OM Cryostat (Microm International, Walldorf, Germany).  
 
3.8.2 Epon-embedding and semi thin sectioning 
 
After fixation in EM fixation eyes were eyes were washed at least 4 times for 30 min in 
0.1 M cacodylate buffer. Eyes were additionally fixed in 1% osmimumtetraoxid and eyes 
were washed again in cocodylate buffer. Eyes were dehydrated in an ascending alcohol 
series (70%, 80%, 90%, 100%). Epon-embeding was carried out after standardized 
methods: Ethanol/Acetone 1:1, 100% Acetone, Epon/Aceton 1:2, Epon/Acetone 2:1, 
100% Epon; curing for 24 h at 60 °C, curing for 48 h at 90 °C. Epon stem A and Epon 
stem B were mixed 1:1 for embedding with 2% DMP-30 (Roth, Karlsruhe, Germany).  
1 µm sections were made from eyes and optic nerves for light microscopy.  
3.8.3 Immunohistochemical staining 
 
Cryo sections were attached to object slides and dried with a hair drier. To dissolve 
embedding medium slides were washed for 5 min in 0.1 M phosphate buffer or 1x TBS. 
After shaking of liquids sections were encircled with a fat pen (PapPen) and incubated in 
blocking solution for 1 h at RT. Afterwards sections were incubated with primary 
antibodies, dissolved in 1:10 blocking solution, overnight at 4 °C. After three washing 
steps (5 min in 0.1 M Php buffer / 1x TBS) the fluorescence labeled secondary antibody, 
diluted in 1:10 blocking solution was added to the sections and incubated for 45 min  
at RT. After three washing steps sections were stained with 1:10 DAPI in Mowiol and 
covered with glass slides. Sections were stored in the dark at 4 °C. 
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Protein Blocking solution Primary antibody Secondary antibody 
Collagen-
Typ-IV  
3% BSA + 0.1% 
Triton X in 0.1 M Php  
Polyclonal Rabbit Anti 
Human Col-IV, 1:500 in 
0.3% BSA + 0.01% 
Triton X in 0.1 M Php  
AffiniPure Donkey Anti 
Rabbit Cy™3, 1:2000 in 
0.3% BSA / 0.1 M Php 
Smooth-
muscle  
α- Actin 
3% BSA + 0,1% 
Triton X in 0.1 M Php  
Monoclonal Rabbit Anti 
Mouse SMA, 1:1000 in 
0.3% BSA + 0.1% 
Triton X in 0.1 M Php 
Chicken a Rabbit Alexa 
Fluor® 488 conjugated in 
0.3% BSA + 0.01% 
Triton X in 0.1 M Php 
Decorin LF 
113  
3% BSA in 0.1 M Php  Polyclonal Rabbit Anti 
Mouse DCN, 1:1000 in 
0.3% BSA in 0.1 M Php  
AffiniPure Donkey Anti 
Rabbit Cy™3, 1:2000 in 
0.3% BSA / 0.1 M Php  
Decorin LF 
136 
3% BSA in 0.1 M Php  Polyclonal Rabbit Anti 
Human DCN, 1:100 in 
0.3% BSA in 0.1 M Php  
AffiniPure Donkey Anti 
Rabbit Cy™3, 1:2000 in 
0.3% BSA / 01 M Php  
CTGF 2%BSA, 0,2% CWFG, 
in 0.1 M Php  
Polyclonal Rabbit Anti 
Human/Mouse CTGF, 
1:400 in 0.2% BSA, 
0.02% CWFG in 0.1 M 
Php  
AffiniPure Donkey Anti 
Goat Cy™3, 1:1000 in 
0.3% Blotto / 0.1 M Php  
Fibronektin  3% BSA + 0.1% 
Triton X in 0.1 M Php  
Polyclonal Rabbit Anti 
Human FN, 1:500 in 
0.3% BSA + 0.01% 
Triton X in 0.1 M Php  
AffiniPure Donkey Anti 
Rabbit Cy™3, 1:2000 in 
0.3% BSA / 0.1 M Php  
GFAP 2%BSA, 0.2% CWFG, 
in 0.1 M Php 
Polyclonal Rabbit Anti 
Mouse GFAP, 1:200 in 
0.2% BSA, 0.02% 
CWFG in 0.1 M Php 
Chicken a Rabbit Alexa 
Fluor® 488 conjugated in 
0.3% BSA + 0.01% 
Triton X in 0.1 M Php 
pAKT 2%BSA, 0.2% CWFG, 
0.1% Trition X in  
1x TBS 
Monoclonal rabbit anti 
mouse/human pAKT, 
1:100 in 0.2% BSA, 
0,02% CWFG, 0.01% 
Triton X in 0.1x TBS 
AffiniPure Donkey Anti 
Rabbit Cy™3, 1:2000 in 
0.2% BSA, 0,02% 
CWFG, 0.01% Triton X 
in 0.1x TBS 
pSMAD2 2%BSA, 0.2% CWFG, 
0.1% Trition X in  
1x TBS 
Monoclonal rabbit anti 
mouse/human 
pSMAD2, 1:100 in 
0.2% BSA, 0,02% 
CWFG, 0.01% Triton X 
in 0.1x TBS 
AffiniPure Donkey Anti 
Rabbit Cy™3, 1:2000 in 
0.2% BSA, 0,02% 
CWFG, 0.01% Triton X 
in 0.1x TBS 
Table 22: Antibodies and dilutions for immunohistochemistry and immunocytochemistry  
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3.8.4. Immunocytochemical staining 
 
Human trabecular meshwork cells, human ONH astrocytes and mouse ON astrocytes 
were fixe das described above. Cells were stained against DCN, FN, Col Type IV or 
GFAP as described in 3.7.2.  
Cover slips were embedded on glass slides with 1:10 DAPI in Mowiol to make the 
nucleus visible. Cover slips were stored at 4 °C till further use.  
 
3.8.5. Contrasting of optic nerves   
 
Contrasting of optic nerves was carried out with paraphenylenediamine as follows:  
500 mg paraphenylenediamine were dissolved in 50 ml ethanol. The solution was stored 
for three days in daylight at RT, till the solution turned dark. Semi-thin sections were 
incubated in the solution for about three min and then washed in ethanol.  
 
3.9 Light and Fluorescence Microscopy 
 
Semi thin sections, immunohistochemical- and immunocytochemical stainings were 
analysed using an Axio Imager Z1 microscope (Carl Zeiss, Göttingen, Germany).  
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4. Results  
 
4.1 Expression analysis of the interaction between TGF-β/CTGF and 
DCN in vitro  
 
Negative regulation of TGF-β by DCN has first been reported in hamster ovary cells in 
1990 (Yamaguchi et al., 1990) and there is also evidence that DCN is able to inhibit the 
profibrotic effects of CTGF via direct binding (Vial et al., 2011). The effects of TGF-β on 
DCN expression and synthesis on the other hand are cell type dependent and there is 
no data on effects of CTGF on DCN.  
In this study we investigate whether TGF-β, CTGF and DCN influence each other’s 
expression and synthesis in human TM cells, human ONH astrocytes and murine ON 
astrocytes. Expression and synthesis values of the untreated control cells were set to 1 
in all analysis.  
 
4.1.1 Human trabecular meshwork cells  
 
TGF-β2 and CTGF contribute to pathologic changes in the outflow tissues in POAG 
(Fuchshofer and Tamm, 2009, Junglas et al., 2009; Junglas et al., 2012). To analyze the 
effects of TGF-β2 and CTGF on the expression and synthesis of DCN human TM cells 
were treated with either 1 ng of TGF-β2 or 25 ng CTGF for 24 h.  
Relative quantification of DCN mRNA showed that DCN expression is significantly 
reduced after 24 h treatment with either 1ng TGF-β2 or 25 ng CTGF (Figure 4.1 A). 
Treatment with 1 ng of TGF-β2 led to a decrease of DCN mRNA to 0.66 ± 0.13 (n = 6, p 
= 0.01) and treatment with 25 ng of CTGF reduced DCN expression to 0.39 ± 0.13 (n = 
5, p = 0.0002). Western blot analyzes of DCN synthesis in human TM cells showed that 
treatment with 1 ng TGFβ-2 led to a down regulation of DCN synthesis to 0.72 ± 0.02 (n 
= 3, p = 0.003) compared to untreated controls after 24 h treatment while CTGF 
treatment reduced DCN synthesis to 0.45 ± 0.07 (n = 3, p = 0.004). α-Tubulin was used 
as a loading control (Figure 9 B and C).  
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Figure 9: TGF-β2 and CTGF treatment reduces DCN expression and synthesis in human TM cells.  
DCN expression is reduced significantly to 0.66 ± 0.13 (n = 6, p ≤ 0.01) after treatment with 1 ng TGF-β2 
and to 0.39 ± 0.13 (n = 5, p ≤ 0.001) after treatment with 25 ng CTGF. DCN expression was normalized to 
GNB2L (A). DCN synthesis was reduced to 0.72 ± 0.02 (n = 3, p ≤ 0.01) compared to untreated controls 
after treatment with 1 ng TGF-β1. Treatment with 25 ng of CTGF led to a reduction of DCN synthesis to 
0.45 ± 0.07 (n = 3, p ≤ 0.01). DCN synthesis was normalized to α-Tubulin (B and C).  
 
To analyze the effects of DCN on TGF-β1, TGF-β2 and CTGF expression and 
synthesis, human TM cells were treated with 1µg of DCN for 24 h. Treatment with 1 µg 
of DCN led to a significant downregulation of TGF-β1 (0.62 ± 0.1, n = 7, p = 0.004), 
TGF-β2 (0.75 ± 0.09, n = 7, p = 0.022) and of CTGF mRNA (0.53 ± 0.13, n = 6, p = 
0.006); Figure 10, A). GNB2L was used as housekeeping gene. Treatment with 1µg 
DCN led a slight but significant reduction of CTGF synthesis to 0.79 ± 0.06 (n = 3, p = 
0.034) was observed (Figure 10 B and C). α-Tubulin was used as loading control to 
normalize CTGF synthesis between samples. 
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Figure 10: DCN reduces growth factor expression and synthesis in human TM cells.  A significant 
downregulation of TGF-β1 (0.62 ± 0.1, n = 7, p = 0.004), TGF-β2 (0.75 ± 0.09, n = 7, p = 0.022) and of 
CTGF mRNA (0.53 ± 0.13, n = 6, p = 0.006) was observed (A). Expression was normalized to GNB2L. 
Treatment with 1 µg of DCN for 24 h led to a significant downregulation of CTGF synthesis to 0.79 ± 0.06 
(n = 3, p ≤ 0.05, B). CTGF bands were normalized to α-Tubulin (C).  
 
4.1.2 Human optic nerve head astrocytes  
 
Astrocytes of the ONH react to TGF-β treatments with upregulation of ECM expression 
(Fuchshofer et al., 2005; Neumann et al., 2008; Zode et al., 2011) and show reactivation 
in POAG (Hernandez and Pena, 1997; Varela and Hernandez, 1997; Wang et al., 2002. 
To analyze the effects of TGF-β2 and CTGF on the expression and synthesis of DCN 
human ONH astrocytes were treated with either 1 ng of TGF-β2 or 50 ng CTGF for 24 h. 
Vice versa human ONH astrocytes were treated with 1 µg of DCN for 24 h. Real Time 
RT-PCR against TGF-β1, TGF-β2, CTGF and DCN was carried out, again GNB2L was 
used as housekeeper. 
Relative quantification of DCN mRNA showed that DCN expression was significantly 
reduced after 24 h treatment with either 1 ng TGF-β2 or 50 ng CTGF (Figure 11 A). 
Treatment with 1 ng of TGF-β2 led to a decrease of DCN mRNA to 0.56 ± 0.13 (n = 6,  
p = 0.015) and treatment with 50 ng of CTGF reduces DCN expression  
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to 0.40 ± 0.09 (n = 5, p = 0.0002). Analysis of DCN synthesis in human ONH astrocytes 
showed that compared to untreated controls treatment with 1 ng TGFβ-2 leads to a 
down regulation of DCN synthesis to 0.71 ± 0.11 (n = 4, p = 0.021) while CTGF 
treatment reduces DCN synthesis to 0.50 ± 0.18 (n = 5, p = 0.009). DCN synthesis was 
normalized to α-Tubulin (Figure 11 B and C).  
 
Figure 11: TGF-β2 and CTGF treatment reduces DCN expression and synthesis in human ONH 
astrocytes.  DCN expression is reduced significantly to 0.56 ± 0.13 (n = 6, p ≤ 0.05) after treatment with 
1ng TGF-β2 and to 0.40 ± 0.13 (n = 5, p ≤ 0.001) after treatment with 50 ng CTGF. DCN expression was 
normalized to GNB2L (A). Treatment with 1 ng TGF-β2 reduces DCN synthesis to 0.71 (± 0.11, n = 4, p ≤ 
0.05), treatment with 50 ng of CTGF reduces DCN synthesis to 0.50 (± 0.18, n = 5, p ≤ 0.01) in 
comparison to untreated control cells (B). DCN bands were normalized to α-Tubulin (C).   
  
As previously reported for other cell types, DCN leads to a significant downregulation of 
TGF-β1 (0.37 ± 0.19, n = 3, p ≤ 0.029) and TGF-β2 (0.27 ± 0.11, n = 5, p ≤ 0.015) and 
CTGF (0.37 ± 0.16, n = 4, p ≤ 0.011) in human ONH astrocytes compared to untreated 
controls (Figure 12). GNB2L was used as housekeeping gene to normalize expression. 
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Figure 12: DCN reduces growth factor expression in human ONH astrocytes.  After 24 h treatment 
with 1 µg of DCN expression of TGF-β1 was decreased significantly to 0.37 (± 0.19, n = 3, p ≤ 0.05),  
TGF-β2 was significantly reduced to 0.27 (± 0.11, n = 5, p ≤ 0.05) and CTGF was significantly reduced to 
0.37 (± 0.16, n = 4, p ≤ 0.05). mRNA expression was normalized to GNB2L.   
 
4.1.3 Murine optic nerve astrocytes  
 
Since human ONH astrocytes are only available in very limited amounts our group 
established a method to isolate and cultivate murine astrocytes of the optic nerve 
(unpublished data). Due to this this study aimed at analyzing if murine ON astrocytes 
react in the same way to treatments with TGF-2, CTGF or DCN as human ONH 
astrocytes do. These experiments will give further insight in how applicable data of 
mouse models is on humans and it gives us the opportunity to isolate astrocytes of 
overexpression- or knockout mouse lines.  
Murine ON astrocytes were treated the same way as human ONH astrocytes. 
Expression of all genes was set against GNB2L.  
DCN expression was reduced to 0.29 ± 0.12 (n = 4, p = 0.0006) after treatment with 1 ng 
TGF-β2 and to 0.45 ± 0.09 (n = 4, p = 0.0004) after treatment with 50 ng of CTGF. In 
human ONH astrocytes CTGF treatment had a stronger negative regulatory effect on 
DCN expression than TGF-β2 treatment, while the reverse is the case in murine ON 
astrocytes (Figure 13 A).  
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Figure 13: TGF-β2 and CTGF treatment reduces DCN expression and synthesis in murine ON 
astrocytes.  Treatment with 1 ng of TGF-β2 for 24 h reduced DCN expression to 0.29 (± 0.12, n = 4, p ≤ 
0.001, A) while treatment with 50 ng CTGF for 24 h reduced it to 0.45 (± 0.09, n = 4, p ≤ 0.001, A). 
Expression was normalized to GNB2L. Amounts of secreted DCN were lowered to 0.66 ± 0.13 (n = 6, p ≤ 
0.05) after TGF-β2 treatment and to 0.65 ± 0.11 (n = 6, p ≤ 0.05) after CTGF treatment in comparison to 
secreted DCN in the media of untreated control cells (B). Secreted DCN was normalized to whole 
secreted protein detected by Sypro Ruby
TM 
(C).   
 
Since it was almost impossible to detect cellular DCN in protein lysate of murine ON 
astrocytes via western blot, amounts of secreted DCN in the media of treated cells were 
quantified using dot blot. Amounts of secreted DCN were set of against whole protein 
content detected with Sypro RubyTM. Amounts of secreted DCN were significantly 
lowered by treatments with TGF-β2 and CTGF (Figure 13 B and C). A reduction to 0.66 
± 0.13 (n = 6, p = 0.032) was observed after TGF-β2 treatment. A reduction to 0.65 ± 
0.11 (n = 6, p = 0.014) was observed after treatment with CTGF.  
DCN treatment reduced expression of TGF-β1, TGF-β2 and CTGF significantly in 
comparison to untreated controls (TGF-β1: 0.56 ± 0.15, n = 6, p = 0.02, TGF-β2: 0.54 ± 
0.13, n = 7, p = 0.006, CTGF: 0.59 ± 0.11, n = 7, p = 0.005, Figure 14). 
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Figure 14: DCN reduces growth factor expression in murine ON astrocytes.  TGF-β1 (0.56 ± 0.15,  
n = 6, p ≤ 0.05), CTGF (0.59 ± 0.11, n = 7, p ≤ 0.01) and TGF-β2 (0.54 ± 0.13, n = 7, p ≤ 0.01) were 
significantly reduced after DCN treatment. mRNA expression was normalized to GNB2L. 
 
4.2 Decorin reduces extracellular matrix production in human 
trabecular meshwork cells, human - and mouse optic nerve astrocytes 
 
Since TGF-β2 and CTGF induce the expression and synthesis of ECM components in 
cell types involved in the pathogenesis of POAG (Fuchshofer et al., 2005; Fuchshofer 
and Tamm, 2009; Neumann et al., 2008; Zode et al., 2011;) it is of great interest to 
investigate whether DCN is able to repress ECM production in these cells. To answer 
this question secreted FN and Col IV in the media of human TM cells were quantified 
using western blot. Furthermore immunocytochemical staining against FN and Col IV 
and quantification of mRNA was carried out. 
Western Blot analysis revealed that DCN treatment leads to a significant reduction of 
secretion of FN and Col IV by human TM cells (Figure 15 A and B) when set against 
whole protein content measured with Sypro RubyTM. FN was reduced to 0.34 ± 0.13 (n = 
3, p ≤ 0.02) and Col IV was reduced to 0.48 ± 0.14 (n = 3, p ≤ 0.04) in comparison to the 
media of untreated control cells. Immunocytochemical staining confirmed a decrease in 
FN and Col IV synthesis after DCN treatment (Figure 15 C and D).  
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Figure 15: DCN reduces ECM synthesis in human TM cells.  A shows densitometry of secreted FN 
and Col IV relative to whole secreted protein of untreated human TM cells and human TM cells treated 
with 1 µg of DCN for 24 h. Treatment with DCN significantly reduced secretion of FN (0.34 ± 0.13, n = 3, p 
≤ 0.05) and Col IV (0.48 ± 0.14, n = 3, p ≤ 0.05). Signals for FN and Col IV were reduced in media of 
human TM cells treated with 1 µg of DCN in comparison to untreated controls (B). Immunocytochemical 
staining against FN and Col IV showed a reduction of FN and Col IV synthesis after DCN treatment (C 
and D).  
 
Real Time RT PCR yielded the results that mRNA expression of both ECM components 
was decreased after DCN treatment (Figure 16). FN mRNA is reduced to 0.34 ± 0.23  
(n = 4, p = 0.008) and Col IV mRNA is reduced to 0.33 ± 0.11(n = 5, p = 0.005).  
 
Figure 16: DCN reduces FN and Col IV mRNA in human TM cells.  FN mRNA is reduced to 0.34 ± 
0.23 (n = 4, p ≤ 0.01) and Col IV mRNA is reduced to 0.33 ± 0.11 (n = 5, p ≤ 0.01) after DCN treatment in 
comparison to untreated control cells. Expression was normalized to GNB2L.  
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Immunocytochemical staining against FN and Col IV on human ONH astrocytes treated 
with 1 µg of DCN showed a reduction of synthesis of both proteins compared to 
untreated controls (Figure 17 A). Analysis of FN and Col IV mRNA expression after DCN 
treatment also showed a significant reduction (FN: 0.49 ± 0.25, n = 4, p = 0.049;  
Col IV: 0.47 ± 0.17, n = 4, p = 0.032, Figure 17 B).  
 
Figure 17: DCN treatment reduces synthesis and expression of FN and Col IV in human ONH 
astrocytes. Immunocytochemical staining showed a reduction of FN and Col IV synthesis after 24h 
treatment with 1µg DCN (A). mRNA expression of FN (0.49 ± 0.25, n = 4, p ≤ 0.05) and Col IV (0.47 ± 
0.17, n = 4, p ≤ 0.05) are significantly depressed after 24h treatment with 1 µg of DCN. mRNA expression 
was normalized to GNB2L.  
 
In murine ON astrocytes treatment with 1 µg DCN leads to a significant reduction in FN 
and Col IV expression (Figure 18). FN expression is reduced to 0.43 ± 0.08 (n = 4, p = 
0.0051) and Col IV expression is reduced to 0.25 ± 0.06 (n = 4, p = 0.0001). Expression 
was normalized to GNB2L.  
 
Figure 18: DCN treatment reduces expression of FN and Col IV murine ON astrocytes.  FN 
expression was reduced to 0.43 ± 0.08 (n = 4, p≤ 0.01) and Col IV expression was reduced to 0.25 ± 0.06 
(n = 4, p ≤ 0.001). Expression was normalized to GNB2L.  
In combination all results show a clear effect of DCN on FN and Col IV. DCN reduces 
both ECM components significantly in the three analyzed cell types (see Table 23).  
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After 24 h 1 µg DCN 
(compared to 
untreated control) 
human TM cells 
human ONH 
astrocytes 
murine ON 
astrocytes 
FN mRNA 0.34 ± 0.23 0.49 ± 0.25 0.43 ± 0.08 
FN protein 0.34 ± 0.13 - - 
Col IV mRNA 0.33 ± 0.11 0.47 ± 0.17 0.25 ± 0.06 
Col IV protein 0.48 ± 0.14 - - 
Table 23: Expression and synthesis of ECM components after DCN treatment in cell types involved 
in the pathogenesis of POAG.  All values are significant.  
 
4.3 DCN activates AKT signaling in murine ON astrocytes  
 
DCN is able to regulate TGF-β activity via two different mechanisms, either via direct 
binding (Yamaguchi et al., 1990) or via upregulating the synthesis of FBN1 via the 
pAKT/AKT pathway (Kaartinen and Warburton, 2003; Schonherr et al., 2005). Binding of 
DCN to IGF-IR leads to phosphorylation of AKT and in the end to an upregulation of 
FBN1 synthesis. Since the previous experiments showed that all cell types investigated 
react to DCN, TGF-β or CTGF treatment in the same way and murine ON astrocytes are 
easiest to obtain, pathway analyses were carried out with murine ON astrocytes only. To 
investigate whether this pathway is activated by DCN in murine ON astrocytes cells 
were treated with 1 µg of DCN for 6 h.  
 
After 6 h of treatment with 1 µg of DCN an increase of pAKT in relation to AKT could be 
observed (Figure 19). The pAKT/AKT ratio of treated cells was 1.36 ± 0.11 (n = 4,  
p = 0.025) compared to untreated control cells (1 ± 0.07, n = 4), meaning that DCN 
treatment leads to an activation of the pAKT/AKT pathway in murine ON astrocytes.  
α-Tubulin was used as loading control to normalize pAKT and AKT.  
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Figure 19: DCN activates AKT signaling in murine ON astrocytes.  pAKT/AKT ratio was significantly 
higher in murine ON astrocytes treated with 1 µg of DCN for 6 h (1.36 ± 0.11, n = 4, p ≤ 0.05) speaking for 
an activation of the pAKT/AKT signaling pathway in this cell type. pAKT and AKT were normalized to α-
Tubulin.  
 
4.4 The negative regulatory effect of DCN on TGF-β1, TGF-β2 and 
CTGF is mediated via pAKT/AKT signaling in murine ON astrocytes.  
 
To analyze if the negative effects of DCN on expression of TGF-β1, 2 and CTGF are 
mediated via pAKT/AKT signaling astrocytes were treated with the AKT signaling 
inhibitor triciribine in combination with DCN. Treatment with DCN resulted in a significant 
downregulation of all three growth factors (Figure 4.13; CTGF: 0.49 ± 0.13,  
n = 6, p = 0.007; TGF-β1: 0.41 ± 0.10, n = 5, p = 0.003; TGF-β2: 0.65 ± 0.13, n = 6,  
p = 0.004) After combined treatment with triciribine and DCN no significant reduction in 
expression of CTGF, TGF-β1,and TGF-β2 could be observed and expression was 
significantly higher when compared to cells treated with DCN only (Figure 20;  
CTGF: 0.81 ± 0.10, n = 5, p = 0.047; TGF-β1: 1.46 ± 0.22, n = 5, p = 0.005;  
TGF-β2: 1. 57 ± 0.57, n = 5, p = 0.038). Due to these results we conclude that the 
reduction of growth factor expression by DCN in murine ON astrocytes is mediated via 
the pAKT/AKT signaling pathway. Expression of all genes was normalized to GNB2L.  
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Figure 20: Inhibition of the pAKT/AKT signaling pathway circumvents negative regulation of TGF-β 
and CTGF by DCN.  After treatment with 1 µg of DCN expression of CTGF (0.49 ± 0.13, n = 6, p ≤ 0.01), 
TGF-β1 (0.41 ± 0.10, n = 5, p ≤ 0.001) and TGF-β2 (0.65 ± 0.13, n = 6, p ≤ 0.001) was significantly lower 
than in untreated controls. Combined treatment with triciribine and DCN did not lead to changes in 
expression compared to untreated controls, but expression was significantly higher than in cells treated 
with DCN only (CTGF: 0.81 ± 0.10, n = 5, p = 0.047; TGF-β1: 1.46 ± 0.22, n = 5, p = 0.005;  
TGF-β2: 1. 57 ± 0.57, n = 5, p = 0.038). Expression was normalized to GNB2L.  
 
4.5 DCN is reduced in the chamber angle of POAG patients  
 
Previous studies showed that DCN is present in cornea, retina and TM (Funderburgh et 
al., 1998; Inatani et al., 1999; Tanihara et al., 1995). Anterior eye segments of POAG 
donors and healthy controls were stained against DCN to analyze whether DCN 
synthesis is altered in the outflow tissues of POAG patients.  
4 sagittal sections of chamber angles of healthy donors and 3 sagittal sections of 
chamber angles of donors affected by POAG were stained against DCN. In all sections 
DCN signal was observed in the sclera, the cornea (not shown), the ciliary muscle (CM), 
the entire TM as well as in the endothelium of SC. Compared to chamber angles of 
healthy controls DCN signal was considerably weaker in all parts of the chamber angles 
of POAG donors (Figure 21). 
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Figure 21: DCN synthesis is reduced in the chamber angle of POAG patients.  Staining against DCN 
revealed that DCN is reduced dramatically in the chamber angle and in the outflow tissue of POAG 
patients. Blue: DAPI, red: DCN, scale bars: 50 µm.  
 
4.6 The influence of CTGF overexpression on DCN in vivo  
4.6.1 Influence of lens-specific overexpression of CTGF on DCN expression and 
synthesis in the region of the TM  
 
Prior to all experiments animals were genotyped at an age of 21 to 25 days. βB1 (Figure 
22 A) and SV40 (Figure 22 B) PCR were carried out. In TG animals SV 40 PCR results 
in a 360 bp band and βB1 PCR results in a 300 bp band while WT animals show no 
band when the PCR product is made visible with EtBr. Only animals displaying a band in 
both PCRs were considered as TG, animals that were positive for only βB1 or SV40 
were excluded from analyses. 
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Figure 22: Results of an exemplary βB1 and SV40 PCR.  Transgenic animals show a 360 bp band in 
SV 40 PCR and a 300 bp band in βB1 PCR. Only animals showing bands in both PCRs were considered 
as TG and used for experiments.  
 
The in vitro results showed a reduction of DCN expression and synthesis after treatment 
with CTGF in TM cells as well as in astrocytes. Due to this we hypothesized that the 
lens-specific overexpression of CTGF in βB1-CTGF mice will lead to a reduced 
expression and synthesis of DCN in the region of the TM, the ONH and the ON.  
8 week old βB-1 CTGF mice and their wildtype littermates were used for experiments.  
Relative quantification of DCN mRNA in the corneo-scleral ring provided first proof of our 
hypothesis. In comparison to wildtype littermates DCN mRNA was reduced in transgenic 
animals (WT = 1.00 ± 0.08, n = 9; TG = 0.66 ± 0.09, n = 7, p = 0.02; Figure 23 A).  
Western blot signals for DCN were weaker in TG animals in comparison to bands of WT 
animals (Figure 23 C). Quantification and normalization against α-Tubulin resulted in a 
significant reduction of DCN synthesis in the corneo-scleral ring of βB1-CTGF mice  
(WT = 1.00 ± 0.01, n = 5, TG = 0.55 ± 0.17, n = 6, p = 0.04; Figure 23 B).  
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Figure 23: DCN expression and synthesis is reduced in the corneo-scleral rim of βB1-CTGF mice.  
A: A lens-specific overexpression of CTGF leads to a significant downregulation of DCN expression in the 
corneo-scleral ring (WT = 1.00 ± 0.08, n = 9, TG = 0.66 ± 0.09, n = 7, p ≤ 0.05). C shows a representative 
western blot for DCN in the corneo-scleral ring of an 8 week old WT animal and its TG littermate.  
DCN was normalized to α-Tubulin. Quantification of DCN bands yielded a significant reduction of DCN 
synthesis (B; WT = 1.00 ± 0.01, n = 5, TG = 0.55 ± 0.17, n = 6, p ≤ 0.05). 
 
Immunohistochemical staining of sagittal sections of 8 week old WT and βB1-CTGF 
mice eyes against DCN showed a positive signal in the retina (not shown), cornea, 
ciliary body, iris and the TM. The signal for DCN was weaker in sagittal sections of eyes 
of βB1-CTGF mice. A weaker signal for DCN could especially be observed in the 
chamber angle (Figure 24). DCN was reduced in the ciliary body, the cornea, the iris and 
in the outflow tissues of βB1-CTGF mice.  
All results prove our hypothesis that overexpression of CTGF leads to a reduction of 
DCN expression and synthesis in the anterior eye segment and especially in the region 
of the TM.    
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Figure 24: DCN signal is reduced in the region of the TM in βB1-CTGF mice.  A positive signal for 
DCN was observed in the sclera, the retina (not shown), the cornea, the iris, the ciliary muscle and the 
TM. Signals for DCN were lower in TG animals when compared to their wildtype littermates. SCL = Sclera, 
CO = Cornea, TM = Trabecular meshwork, CM = Ciliary muscle. Red = DCN, blue = DAPI,  
scale bars: 20µm.  
 
4.6.2 Influence of lens-specific overexpression of CTGF on DCN in the ON  
 
Intriguingly we could not detect changes in DCN mRNA or protein amounts in the ON of 
8 week old βB1-CTGF mice in comparison to WT animals. DCN expression was 1 ± 
0.09 in WT mice while it was 0.96 ± 0.13 in βB1-CTGF mice (n = 5, p = 0.84,  
Figure 25 A). Protein amounts were also not changed in TG animals (WT= 1 ± 0.38,  
TG = 1.21 ± 0.22, n = 5, p = 0.46, Figure 25 B and C).  
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Figure 25: Lens-specific overexpression of CTGF does not influence DCN in the ON.  DCN 
expression was 1 ± 0.09 in WT mice while it was 0.96 ± 0.13 in βB1-CTGF mice (n = 5, p ≥ 005). Protein 
synthesis was slightly higher in TG animals, but no significant changes could be found (WT= 1 ± 0.38,  
TG = 1.21 ± 0.22, n = 5, p ≥ 0.05). Expression was normalized to GNB2L, synthesis was normalized to α-
Tubulin.  
 
4.7 Decorin deficiency in 129SV/BL Swiss/CD1 mice mimics POAG 
 
4.7.1 Verification of DCN knockout  
 
All animals used for experiments were genotyped at an age of 21 to 25 days. DCN 
genotyping PCR results in a single 250 bp band in a DCN-/-, a single 161 bp band in a 
wildtype and both bands in a heterozygous (DCN+/-) animal (Figure 26). 
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Figure 26: Result of an exemplary DCN genotyping PCR.  DCN
-/- 
animals show a single 250 bp band, 
WT animals a single 161 bp band. Heterozygous animals (DCN
+/-
) show both bands. A heterozygous 
animal was used as a positive control. H2O was used in the negative control instead of DNA. 
 
Before first experiments with DCN mice were carried out we verified the knockout of 
DCN in the eye by western blot. DCN signal was detectable in the anterior eye segment 
and the retina of WT animals, whereas no signal for DCN was detectable in the anterior 
eye segment or in the retina of DCN-/- animals by western blot analysis (Figure 27).  
 
Figure 27: Verification of DCN knockout in the anterior eye segment (AAS) and in the retina.  While 
western blot for DCN showed bands for the AAS and the retina of WT animals no bands could be detected 
in DCN
-/-
 animals.  
 
4.7.2 Histological analysis of the DCN-/- animals  
 
To ensure that DCN deficiency does not cause developmental changes in eye 
morphology we analyzed sagittal sections of eyes of DCN-/- and WT mice of different 
ages by light microscopy.  
Regarding the entire eye no visible morphological changes could be seen in the eyes of 
DCN-/- mice. Cornea, retina, iris, chamber angle and papilla of a 9 month old  
DCN-/- mouse do not show differences that can be observed by light microscopy 
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compared to a WT littermate (Figure 28). Both eyes show a normally developed TM and 
SC. The endothelium of SC looked similar in WT and DCN-/- animals and possessed 
vacuoles (pictures not shown), indicating that AH outflow is not hindered by severe 
structural changes.  
We could not monitor differences in the chamber angle and the papilla of a 2 month old 
WT animal and its DCN-/- littermate (Figure 29). The chamber angle is open in both 
animals and there are no visible differences in structure and organization of the TM. The 
papilla does not show signs of excavation in the DCN-/- animal. The same observation 
was made in 6 month old animals (Figure 30). There is no visible blocking of AH outflow 
in the TM that could cause elevation of IOP, and the papilla is not obviously excavated in 
the DCN deficient animal.   
All in all we conclude that the knockout of DCN in mice does not lead to morphological 
changes in the eye that can be observed on light microscopy levels. We could not find 
changes in the region of the TM that would hinder AH outflow and thereby increase IOP 
and papilla of DCN-/- mice show no obvious signs of excavation at an age of 2, 6 or 9 
months.  
 
 
 
Figure 28: Whole eye of a 9 month old DCN WT mouse and its DCN
-/- 
littermate.  No morphological 
differences could be observed. Scale bars: 500 µm.  
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Figure 29: Chamber angle and papilla of a 2 month old DCN WT mouse and its WT littermate.  The 
chamber angle shows no structural changes and the papilla shows no signs of excavation in the  
DCN
-/-
 mouse. Co: Cornea, I: Iris, CM: Ciliary muscle, TM: Trabecular meshwork, Re: Retina, ONH: Optic 
nerve head. Scale bars: 50 µm.  
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Figure 30: Chamber angle and papilla of a 6 month old DCN WT mouse and its WT littermate.  The 
chamber angle shows no structural changes and the papilla shows no signs of excavation in the  
DCN
-/-
 mouse. Co: Cornea, I: Iris, CM: Ciliary muscle, TM: Trabecular meshwork, Re: Retina, ONH: Optic 
nerve head, ON: Optic nerve. Scale bars: 50 µm. 
 
4.7.3 DCN-/- 129SV/BL Swiss/CD1 mice show elevated IOP and loss of optic nerve 
axons 
 
An elevated IOP is the main risk factor to develop POAG (Collaborative-Normal-
Tension-Glaucoma-Study-Group, 1998; Gordon et al., 2002; Johnson et al., 2002; Leske 
et al., 2003). We hypothesize that DCN deficiency leads to an increase of TGF-β and 
CTGF and thereby to an increased outflow resistance in the TM. To verify this 
hypothesis we measured IOP of DCN-/- and wildtype animals every four weeks for one 
year. Animals were grouped by age into 5 groups (see Figure 31). An increase of IOP 
over time was observed in WT and in DCN-/- mice, but while over one year an increase 
of 8.45 mmHg was recorded in DCN-/- mice, increase in IOP was 6.01 mmHg in WT 
mice. In 1 month old animals there was no difference in IOP between WT and DCN-/- 
mice, but in all older animals IOP was significantly higher in DCN-/- animals than in WT 
controls (for exact values see Table 24).  
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Figure 31: IOP is significantly elevated in DCN
-/- 
mice of different ages.  IOP is not elevated in 1 
month old DCN
-/-
 mice in comparison to WT animals. In DCN
-/-
 mice of 2 – 4 month, 5 – 8 month, 9 – 11 
month and 12 month IOP is significantly higher than in WT controls. Circles represent max. outliers, red 
lines mark median (* p ≤ 0.05, ** p ≤ 0.01).  
 
 
 1 month 2 – 4 months 5 – 7 months 8 – 10 months 12 months 
DCN-/- 12.93 ± 2.63 16.74 ± 2.87 17.22 ± 2.76 18.73 ± 4.21 21.38 ± 4.28 
WT 12.35 ± 1.80 15.65 ± 3.26 15.65 ± 2.87 16.90 ± 2.63 18.36 ± 3.49 
p-Value  0.022 0.011 0.004 0.008 
n DCN-/- 42 98 94 96 30 
n WT 32 82 62 80 26 
Table 24: IOP values of DCN
-/-
 and WT mice ± STD.   
 
To analyze if the increased IOP leads to the loss of optic nerve axons, axon numbers of 
DCN-/- and wildtype mice of 2, 3, 6 and 12 months were counted. Optic nerve sections of 
DCN-/- mice showed larger areas devoid of axons than cross sections of wildtype 
littermates (see Figure 32 A). Areas devoid of axons indicate formation of glial scars 
since dead axons get replaced by ECM material. Quantification of optic nerve axons 
revealed a significant difference in axon numbers in mice of 3, 6 and 12 months (Figure 
32 B). Axon numbers of all age groups and p-values are displayed in table 25. 
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Intriguingly axons numbers did not decrease with age as expected. Axon numbers in  
2 month old WT and DCN-/- mice are not different, but at an age of 3 months DCN-/- have 
significantly less axons in the optic nerve than WT littermates. Axon numbers only 
decrease in DCN-/- mice between 2 and 3 months. In WT mice axon numbers were 
stable at all ages analyzed and in DCN-/- mice older than 3 months.    
 
 
Figure 32: Decorin 
-/-
 mice have less optic nerve axons than their wildtype littermates.  A: optic 
nerve cross sections of 12 month old WT and DCN
-/-
 mice. DCN
-/- 
mice show larger areas devoid of axons 
(right, white arrows). B: Number of optic nerve axons of 2, 3, 6 and 12 month old WT and DCN
-/-
 mice. 3 to 
12 month old DCN
-/-
 animals have significantly less axons than WT animals. Means ± STD.  
Scale bars: 50 µm, * p ≤ 0.05.  
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 2 months 3 months 6 months 12 months 
DCN-/- 45664 ± 400 37156 ± 5183 37970 ± 3232 37886 ±1873 
WT 45954 ± 2755 47080 ± 5312 45447 ± 4576 44329 ± 5555 
p-Value 0.881 0.022 0.017 0.033 
n DCN-/- 5 5 5 6 
n WT 5 5 5 6 
Table 25: Axon number of DCN
-/-
 and WT mice of different ages.  Means ± STD.  
 
4.7.4 Expression and synthesis of key players in POAG is altered in the corneo-
scleral ring of DCN-/- 129SV/BL Swiss/CD1 mice 
 
4.7.4.1 CTGF 
 
Junglas et al. showed that a lens-specific overexpression of CTGF leads to a 
glaucomatous phenotype in mice (Junglas et al., 2012) and our in vivo and in vitro data 
showed negative reciprocal effects of DCN on CTGF. Therefore we conclude that a lack 
of DCN should lead to an increased expression and synthesis of CTGF in vivo. To test 
for this hypothesis we analyzed CTGF mRNA and protein in corneo-scleral rings of 8 
week old DCN-/- mice and their WT littermates. Real Time RT PCR showed a more than 
six-fold increase in CTGF expression in the corneo-scleral ring of DCN-/- mice in 
comparison to WT animals (WT = 1.00 ± 0.19, DCN-/- = 6.55 ± 2.03, n = 6, p = 0.037, 
figure 33 A). CTGF expression was normalized to RPL32. 
Western blot analysis of CTGF synthesis in the corneo-scleral ring showed that CTGF 
synthesis is significantly higher in the corneo-scleral ring of DCN-/- mice (Figure 33 B 
and C). CTGF synthesis in the corneo-scleral ring of WT mice was 1 ± 0.46 (n = 5) while 
CTGF synthesis in DCN-/- mice was 3.27 ± 1.42 (n = 4, p = 0.040). Synthesis of CTGF 
was normalized to α-Tubulin.  
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Figure 33:CTGF expression and synthesis is increased in the corneo-scleral ring of DCN
-/-
 mice.  
Relative Quantification of CTGF mRNA resulted in the observation that CTGF mRNA is significantly 
elevated in the corneo-scleral ring of DCN
-/-
 mice in comparison to WT animals of the same age   
(WT = 1.00 ± 0.19, DCN
-/-
 = 6.55 ± 2.03, n = 6, p ≤ 0.05, A). CTGF expression was normalized to RPL32. 
B shows densitometry of CTGF signals of corneo-scleral rings of DCN
-/-
 and WT mice normalized to  
α-Tubulin. CTGF signal in WT mice was 1 ± 0.46 (n = 5) while CTGF signal in DCN
-/-
 mice was 3.27 ± 
1.42 (n = 4, p ≤ 0.05). C shows an exemplary western blot against CTGF and the housekeeper α-Tubulin. 
 
Immunohistochemical staining against CTGF showed elevated synthesis of CTGF in the 
whole eye of 8 week old DCN-/- mice in comparison to their WT littermates (Figure 34). 
Staining confirmed the results of Real Time RT PCR and western blot. Signal for CTGF 
was brighter in the region of the TM in DCN deficient animals. Furthermore a brighter 
signal for CTGF was observed in retina, sclera, cornea, ciliary body and iris of DCN-/- 
mice. Negative controls (not shown), testing for unspecific binding of the secondary 
antibody, showed no signal.  
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Figure 34: Signal for CTGF is stronger in the anterior eye of DCN
-/-
 mice than in WT animals.  
Immunohistochemical staining against CTGF showed higher synthesis of CTGF in the anterior eye of 
DCN deficient animals. CTGF synthesis seems to be elevated in the Retina (Re), the ciliary muscle (CM), 
the cornea (Co) and in the region of the trabecular meshwork (TM). Scale bars: 20 µm.  
 
4.7.4.2 TGF-β2 
 
TGF-β2 is also a key player in POAG. For all cell types analyzed this study could show 
negative reciprocal effects of TGF-β2 and DCN. So we hypothesize that a lack of DCN 
should increase expression of TGF-β2 in mice. Expression of TGF-β2 was significantly 
higher in the corneo-scleral ring DCN deficient animals (Figure 35). TGF-β2 mRNA 
expression is significantly higher in 8 week old DCN-/- mice (4.45 ± 2.15, n = 6) in 
comparison to WT mice (1 ± 0.58, n = 7, p = 0.044). 
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Figure 35: TGF-β2 mRNA expression is elevated in the corneo-scleral ring of DCN
-/- 
mice.  TGF-β2 
expression was 1 ± 0.58 in WT (n = 7) and 4.45 ± 2.15 in DCN
-/- 
(n = 6, p ≤ 0.05) meaning a significant 
upregulation of TGF-β2 expression in the corneo-scleral ring of DCN deficient animals. 
 
4.7.4.3 FN and Col IV 
 
It has been described previously that CTGF increases FN and Col IV expression and 
synthesis in TM cells and astrocytes (Fuchshofer et al., 2005, Junglas et al., 2009) and 
that βB1-CTGF mice have elevated amounts of FN in the iridocorneal angle (Junglas et 
al., 2012). Therefore we assumed that the elevation in CTGF expression and synthesis 
will lead to an increased FN and Col IVexpression and synthesis in the corneo-scleral 
ring of DCN-/- mice. In order to prove this we analyzed the corneo-scleral rings of 8 week 
old DCN-/- and WT mice regarding FN and Col IV expression and synthesis.  
FN expression is significantly higher in the corneo-scleral ring of DCN-/- mice. FN 
expression in WT mice was 1 ± 0.13 (n = 9) while FN expression in DCN-/- mice was 
3.49 ± 1.50 (n = 6; p = 0.50; Figure 36). Densitometry of western blots against FN in the 
corneo-scleral rings of WT and DCN-/- mice showed a significant increase in FN 
synthesis. FN synthesis in WT mice was 1 ± 0.09 (n = 5) while synthesis in DCN-/- mice 
was 1.82 ± 0.27 (n = 5, p = 0.0419). FN synthesis was normalized to α-Tubulin (Figure 
36 B and C).  
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Figure 36: FN expression and synthesis is elevated significantly in the corneo-scleral ring of DCN
-/-
 
mice.  A: FN expression is significantly higher in the corneo-scleral ring of DCN
-/-
 mice (WT = 1 ± 0.13, 
DCN
-/-
 = 3.49 ± 1.50 (n = 9, p ≤ 0.05). Expression was normalized to RPL32. B shows densitometry of  
FN bands after normalization to α-Tubulin. Western blot analysis revealed a significant increase of  
FN synthesis in DCN
-/-
 animals (1.82 ± 0.27) than in WT littermates (1 ± 0.09; n = 5, p ≤ 0.05).   
 
For further proof of an elevated synthesis of FN sagittal sections of eyes of 8 week old 
WT and DCN-/- mice were stained against FN. We observed an increase in FN signal in 
the entire anterior eye segment of DCN-/-, but we also noticed that FN synthesis is 
stronger in the region of the TM and the cornea (Figure 37). Negative controls (not 
shown), testing for unspecific binding of the secondary antibody, showed no signal.  
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Figure 37: Immunohistochemical staining for FN is stronger in the anterior eye of DCN
-/-
 mice.  
Signal for FN is stronger especially in the region of the trabecular meshwork (TM) in the anterior eye 
segments of DCN
-/-
 mice. But FN synthesis seems also to be elevated in the Retina (Re), the ciliary 
muscle (CM) and the cornea (Co).Blue: DAPI, red: FN. Scale bars: 20 µm. 
 
The knockout of DCN also led to a highly significant upregulation of Col IV expression in 
the corneo-scleral ring (WT = 1 ± 0.05, DCN-/- = 3.66 ± 0.72, p = 0.01, Figure 38). 
 
Figure 38: Col IV expression is significantly increased in the corneo-scleral ring of DCN
-/-
 mice.  Col 
IV expression was upregulated significantly in the corneo-scleral ring of DCN deficient animals compared 
to WT littermates (WT = 1 ± 0.05, DCN
-/-
 = 3.66 ± 0.72, p ≤ 0.01). Expression was normalized to RPL32. 
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4.7.5 TGF-β and CTGF expression are altered in the optic nerve of DCN-/- 129SV/BL 
Swiss/CD1 mice 
 
Since the ON also undergoes changes in POAG, which are most likely induced by 
pathological amounts of TGF-β and CTGF, we analyzed if the complete absence of 
DCN affects expression of TGF-β1, TGF-β2 and CTGF in the optic nerve.  
We could demonstrate that the knockout of DCN leads to a significant increase in 
expression of all three growth factors in the optic nerve (Figure 39). TGF-β1 was  
1 ± 0.15 (n = 9) in WT ON and 1.83 ± 0.23 (n = 10) in DCN-/- ON (p = 0.040). TGF-β2 
was 1 ± 0.13 in WT (n = 9) and 1.85 ± 0.20 (n = 10) in DCN-/- (p = 0.036). CTGF was 
also significantly upregulated in DCN-/- ON (1.84 ± 0.23, n = 7) in comparison to WT 
mice (1 ± 0.15, n = 7, p = 0.044). Expression was normalized to RPL32. 
 
 
Figure 39: Expression of CTGF, TGF-β1 and TGF-β2 is elevated in the optic nerve of DCN deficient 
mice.  CTGF was increased to 1.84 ± 0.23 in DCN
-/- 
ON (n = 7) in comparison to WT ON (1 ± 0.15, n = 7, 
p ≤ 0.05). TGF-β1 expression in the ON of DCN
-/- 
mice is significantly increased to 1.83 ± 0.23 (n = 10) 
compared to WT animals (1 ± 0.15 n = 9, p ≤ 0.05) and TGF-β2 levels are also significantly higher in ON 
of DCN deficient animals (WT = 1 ± 0.13, n = 9; DCN-/- = 1.85 ± 0.20, n = 10, p ≤ 0.05). Expression of all 
genes was normalized to RPL32.  
 
To evaluate if the knockout of DCN also leads to elevated synthesis of CTGF in the ON 
we carried out immunohistochemical staining against CTGF in sagittal sections of eyes 
of 12 week old DCN WT and DCN-/- animals. Signal for CTGF was higher in the ON of 
DCN-/- mice compared to their WT littermates (Figure 40). Especially in the region of the 
ONH we could observe an increase in CTGF signal. Negative controls (not shown), 
testing for unspecific binding of the secondary antibody, showed no signal. 
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Figure 40: CTGF synthesis is elevated in the ON of DCN deficient mice.  Signal for CTGF was 
stronger in DCN deficient ON, especially in the region of the ONH. Blue: DAPI, red: CTGF. Re: retina,  
ON: Optic nerve, ONH: optic nerve head, scale bars: 20 µm.  
 
4.7.6 Astrocytes of the laminar region of DCN-/- 129SV/BL Swiss/CD1 mice show 
signs of reactivation  
 
Reactivation of astrocytes in the region of the LC is one typical observation in the 
glaucomatous ONH. Reactivation of astrocytes shows in increased amounts of GFAP 
synthesis and in morphological changes, like thickening of processes and hypertrophy of 
the cell body (Hernandez and Pena, 1997; Varela and Hernandez, 1997; Wang et al., 
2002). To check for signs of astrocyte reactivation on the ONH of DCN deficient mice, 
we made tangential sections through the glial lamina of 12 week old DCN-/- and WT 
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mice. Tangential sections were stained against GFAP and nuclei were made visible with 
DAPI (Figure 41).  
 
Figure 41: GFAP synthesis and astrocyte morphology is altered in the glial lamina of DCN
-/-
 mice.  
Signal for GFAP was stronger in the glial lamina of DCN
-/-
 mice. Additionally GFAP negative spaces 
between astrocytes appear smaller and processes seem thickened. Blue: DAPI, red: GFAP.  
Scale bars: 100 µm.  
 
Staining against GFAP in the glial lamina indicated reactivation of astrocytes of that 
region. GFAP signal was increased in the glial lamina of DCN-/- mice in comparison to 
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WT animals. Accessorily we observed changes in astrocyte morphology. Processes 
appeared shortened and thickened and areas negative for GFAP, meaning spaces 
between astrocytes, through which axons can pass, were smaller. Therefore we 
conclude that a knockout of DCN leads to reactivation of astrocytes in the region of the 
glial lamina.  
 
4.7.7 Astrocytes of the glial lamina engage in pAKT/AKT signaling 
 
Since staining pattern for pAKT in ON cross sections indicated that astrocytes are a 
source of pAKT in this region, we carried out double staining against pAKT and GFAP in 
tangential sections of the glial lamina of 12 week old animals to check for co-localization 
of the two proteins.  
We found a co-localization of pAKT and GFAP in glial lamina (Figure 42), meaning that 
pAKT/AKT signaling is active in astrocytes of this region.  
 
 
Figure 42: Co-localization of pAKT and GFAP in the glial lamina.  Staining against GFAP (green) and 
pAKT (red) revealed co-localization of both proteins, meaning that pAKT/AKT signaling is active in the glial 
lamina. Blue: DAPI, scale bars: 50 µm.  
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4.7.8 pAKT is reduced in the eye of DCN-/- 129SV/BL Swiss/CD1 mice  
 
Since DCN can bind to IGF-IR and thereby activate the pAKT/AKT signaling pathway 
(Schonherr et al., 2005), the absence of DCN in the eye should lead to a decreased 
phosphorylation level of AKT. To check if activation of the pAKT/AKT signaling pathway 
is reduced in the eye of DCN deficient mice we carried out pAKT staining in sagittal and 
tangential sections of 12 week old WT and DCN-/- mice.  
We found that signal for pAKT is reduced in the chamber angle and the TM (Figure 43), 
the retina (Figure 44) and in the ON (Figure 45) of DCN-/- mice compared to pAKT signal 
in these regions in WT mice.  
 
 
Figure 43: pAKT signal is reduced in the chamber angle of DCN
-/-
 mice compared to WT littermates.  
Staining intensity in the chamber angle and in the region of the TM was reduced in 12 week old  
DCN
-/-
 mice. Blue: DAPI, red: pAKT, Re: Retina, TM: Trabecular meshwork, CM: Ciliary muscle,  
scale bars: 50 µm.  
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Figure 44: pAKT signal is reduced in the retina of DCN
-/-
 mice compared to WT littermates.  Staining 
intensity in the retina was reduced in 12 week old DCN
-/-
 mice. Distribution of pAKT staining indicates that 
Mueller cells are the main source of pAKT synthesis. Blue: DAPI, red: pAKT, GCL: Ganglion cell layer, 
IPL: Inner plexiform layer, OPL: Outer plexiform layer, RL: Receptor layer, RPE: Retinal pigment 
epithelium, scale bars: 50 µm. 
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Figure 45: pAKT signal is reduced in the ON of DCN
-/-
 mice compared to WT littermates.  Staining 
intensity in the ON was reduced in 12 week old DCN
-/-
 mice. Distribution of pAKT staining indicates that 
astrocytes are the main source of pAKT synthesis. Blue: DAPI, red: pAKT, scale bars: 50 µm. 
 
 
4.7.9 Gene expression in the outflow tissues of DCN deficient 129SV/BL 
Swiss/CD1 mice  
 
Overall, our in vitro data clearly indicate that lack of DCN in TM and ON is associated 
with an increased activity of TGF-β/CTGF signaling. To obtain more detailed information 
on the molecular mechanisms that are behind the interactions of DCN with TGF-β/CTGF 
signaling and might cause high IOP and POAG, we applied deep sequencing technique. 
RNA was isolated from corneo-scleral rings, including the TM outflow pathways, of  
DCN-/- mice and their WT littermates at the age of three months. 258 genes were 
identified that differed in their expression pattern between DCN-/- mice and WT 
littermates with an expression ratio difference of either greater than 0.5 log2-fold or less 
than -1.0 log2-fold and a p-value of ≤ 0.05. Quite intriguingly, our first screening of the 
data showed distinct changes in genes and pathways that are known to be involved in 
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the pathogenesis of POAG. Accordingly, we detected a significant upregulation in the 
expression of ECM molecules such as collagen type I and IV, alterations in the 
expression of cytoskeletal genes like tropomyosin, and changes in the expression of 
members of the Rho, WNT and TGF-β signaling pathways (Table 26). Furthermore 
multiple genes that have previously been associated with glaucoma were either up- or 
down regulated in the corneo-scleral ring of DCN-/- mice (Table 27).  
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GO Term counts p-value 
cell adhesion 111 7.30E-10 
regulation of small GTPase mediated signal 
transduction 
48 1.50E-05 
intracellular transport 76 3.60E-05 
transmembrane receptor protein tyrosine kinase 
signaling pathway 
41 5.00E-05 
cell-cell signaling 54 1.40E-04 
extracellular matrix organization 32 3.40E-04 
cell-cell adhesion 44 6.10E-04 
regulation of Ras protein signal transduction 36 6.30E-04 
TGF beta receptor pathway 24 1.80E-03 
eye development 31 1.80E-03 
protein kinase cascade 42 2.10E-03 
camera-type eye development 26 3.80E-03 
actin filament-based process 32 5.50E-03 
endocytosis 33 8.20E-03 
calcium ion transport 23 1.20E-02 
negative regulation of apoptosis 39 1.30E-02 
monosaccharide metabolic process 32 1.80E-02 
regulation of transferase activity 33 1.80E-02 
regulation of cell proliferation 76 1.80E-02 
negative regulation of cell death 39 1.90E-02 
lipid biosynthetic process 44 2.00E-02 
regulation of protein kinase activity 31 2.10E-02 
cell migration 38 2.20E-02 
regulation of apoptosis 77 2.40E-02 
MAPKKK cascade 21 2.40E-02 
protein complex assembly 36 2.50E-02 
Wnt receptor signaling pathway 23 2.70E-02 
positive regulation of catalytic activity 40 3.00E-02 
regulation of kinase activity 31 3.10E-02 
actin cytoskeleton organization 27 3.80E-02 
positive regulation of transferase activity 23 3.90E-02 
positive regulation of cell communication 30 4.10E-02 
Table 26: Significantly enriched gene ontology (GO) terms detected in differentially expressed 
RNA pattern between 3 month old DCN
-/-.
mice and their wild-type littermates.  Only those terms 
which reported a p-value of ≤ 0.05 and count number ≥ 19 genes were selected for the analysis. 
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Genes log2 (fold change) p- value 
branched chain amino acid 
transaminase 1 
-1.92 0.0393 
leucine rich repeat and immunoglobin-
like domain-containing protein 1 
-1,72 0.0175 
versican -1.35 0.0174 
fibromodulin  -1.20 0.0122 
BCL2 associated X protein -1.06 0.0246 
ras homolog gene family member A 0.55 0.0146 
transporter associated with antigen 1 0.61 0.0115 
uncoupling protein 2 0.61 0.0156 
transporter associated with antigen 2 0.70 0.0423 
collagen type IV 0.70 0.0043 
EGF receptor 0.71 0.0196 
transglutaminase 2 0.78 0.0122 
exportin for tRNA 0.86 0.0205 
small mother agains decapentaplegic 7  0.95 0.0412 
signal transducer and activator of 
transcription 6 
0.95 0.0031 
wnt4 1.04 0.0313 
C-X-C motif chemokine 10 1.27 0.0370 
signal transducer and activator of 
transcription 1 
1.33 0.0010 
matrix metalloproteinase-2 1.77 0.0453 
tafazzin 1.80 0.0104 
tropomyosin 3 1.80 0.0155 
Table 27: Alteration of genes associated with glaucoma in the corneo-scleral ring of DCN
-/-
 mice.  
Various genes that have previously been described in the context of glaucoma are up or down regulated 
in the corneo-scleral ring of DCN
-/-
 mice. Only genes with a p-value ≤ 0.05 were selected. 
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4.8 DCN deficient mice in a pure CD1 background show elevated IOP 
and loss of optic nerve axons  
 
The genetic background of mice strongly influences IOP. Average IOP ranges from 10 to 
20 mm/Hg in different mouse strains (Savinova et al., 2001). Moreover CD1 mice are 
more susceptible to glaucomatous damage than other mice strains (Cone et al., 2010; 
Cone et al., 2012). Due to that we back-crossed DCN+/- mice of a mixed 129SV/BL 
Swiss/CD1 background into a pure CD1 background over 8 generations. DCN+/- of the 
8th generation were cross-bred to get DCN-/- and WT littermates for experiments.  
IOP was measured at 12 weeks. Afterwards animals were sacrificed and eyes were 
used for immunohistochemistry and light microscopy. Total number of ON axons was 
quantified.  
 
Figure 46: 12 week old DCN
-/-
 mice in a pure CD1 background have a higher IOP and less optic 
nerve axons than their WT littermates.  A shows an exemplary ON cross section of a 12 week old DCN 
WT and a 12 week old DCN
-/- 
mouse. There are no obvious structural changes in the ON of the DCN 
deficient animal. IOP values of DCN
-/-
 animals are significantly higher than IOP values of WT mice of the 
same age (B). Furthermore numbers of ON axons are significantly lower in DCN
-/- 
mice compared to WT 
littermates (C). Exact numbers are listed in Table 4.5. All values are means ± STD. Scale bars: 50 µm.   
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 axon numbers IOP values [mm/Hg]  
DCN-/- 
 12 weeks 
42457 ± 1047 20.70 ± 3.33 
WT  
12 weeks 
48852 ± 1907 17.32 ± 2.73 
p-Value 0.046 0.031 
n DCN-/- 3 8 
n WT 4 10 
Table 28: Axon numbers and IOP of DCN
-/-
 and WT mice in a pure CD1 background.  All values are 
mean ± STD.  
 
IOP was significantly elevated in DCN-/- CD1 mice when collated with IOP in 
WTlittermates (Figure 46). Optic nerve cross sections of WT CD1 and DCN-/- CD1 mice 
showed no apparent differences regarding areas devoid of axons (Figure 46 A). 
Quantification of ON axons showed that with the elevated IOP comes a loss of axons in 
the ON of DCN-/- mice (Figure 46 C). Exact IOP values and numbers of ON axons are 
listed in Table 28.  
 
4.9 Comparison of IOP and axons numbers in DCN-/- mice in different 
backgrounds  
 
We could show that 12 week old CD1 WT mice have a significantly higher IOP than  
12 week old SV129/BL Swiss/CD1 mice. IOP of CD1 WT mice was 17.40 ± 2.73  
(n = 10) and 14.75 ± 3.42 in 129SV/BL Swiss/CD1 mice (n = 20, p = 0.042).  
DCN-/- CD1 mice also had a significantly higher IOP than DCN-/- 129SV/BL Swiss/CD1 
animals (DCN-/- CD1: 20.07 ± 3.33, n = 8, DCN-/- 129SV/BL Swiss/CD1: 15.91 ± 4.10,  
n = 34, p = 0.004). While there was no difference in IOP between WT 129SV/BL 
Swiss/CD1 and DCN-/- 129SV/BL Swiss/CD1 at an age of 12 weeks, DCN-/- CD1 mice 
had an significantly higher IOP than WT CD1 mice at the same age (p = 0.031, Figure 
47).  
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Figure 47: IOP is higher in 12 week old DCN CD1 mice as in 12 week old DCN SV129/BL Swiss/CD1 
mice.  IOP is significantly higher in 12 week old CD1 mice (17.40 ± 2.73, n = 10) than in 12 week old 
129SV/BL Swiss/CD1 (14.75 ± 3.42, n = 20, p ≤ 0.05) mice without genetic modification. Also in DCN
-/-
 
CD1 (20.07 ± 3.33, n = 8)
 
animals IOP was significantly higher at an age of 12 weeks than in DCN
-/-
 
129SV/BL Swiss/CD1 mice (15.91 ± 4.10, n = 34, p ≤ 0.05) of the same age. DCN
-/- 
CD1 mice had a 
significantly higher IOP than WT CD1 mice. 129SV is used as abbreviation for 129SV/BL Swiss/CD1, 
circles represent max. outliers. All values are mean ± STD.  
 
Axon numbers were not different between CD1 and 129SV/BL Swiss/CD1 mice with or 
without a knockout of DCN (for exact numbers and p-values see table 29).  
 
 WT CD1 DCN-/- CD1 
WT 129SV/BL 
Swiss/CD1 
DCN-/- 129SV/BL 
Swiss/CD1 
Axon 
numbers 
48852 ± 1907 42457 ± 1047 47080 ± 5312 37156 ± 5183 
n 4 3 5 5 
p-Value   0.602 0.185 
Table 29: Axon numbers of 12 week old CD1 and 129SV/BL Swiss/CD1 mice with our without 
knockout of DCN are not different.  All values are mean ± STD.   
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5. Discussion  
5.1 Summary 
 
It was the aim of this study to investigate reciprocal effects of TGF-β2, CTGF and DCN 
in cell types involved in the pathogenesis of POAG and to analyze the influence of DCN 
on expression and synthesis of ECM components in these cell types. In vivo βB1-CTGF 
mice with a lens specific overexpression of CTGF were analyzed regarding DCN levels 
in the region of the TM and the ON. Further this study aims to elucidate the effects of 
DCN deficiency in mice on morphological structures and molecular factors that are 
involved in the pathology of POAG.  
Treatments with TGF-β2 or CTGF significantly reduced DCN expression and synthesis 
in all cell types, vice versa DCN treatment reduced expression of TGF-β1, 2 and CTGF 
in all cell types as well as CTGF synthesis in human TM cells. Besides, DCN treatment 
reduced expression and synthesis of ECM components and led to an activation of the 
pAKT/AKT signaling pathway. Inhibition of the pAKT/AKT signaling pathway inhibited the 
negative regulatory effect of DCN on TGF-β1, 2 and CTGF.  
In vivo lens specific overexpression of CTGF results in a downregulation of DCN 
expression and synthesis in the region of the TM, but does not influence DCN levels in 
the ON.  
DCN deficiency leads to glaucomatous changes in mice. The DCN knockout does not 
result in developmental changes of chamber angle morphology, but leads to a 
significantly elevated IOP in DCN deficient animals older than 8 weeks and induces the 
loss of ON axons in mice older than 12 weeks. RNA sequencing revealed that multiple 
pathways and genes known to be related to glaucoma are significantly altered in the 
corneo-scleral ring of 12 week old knockout animals. Furthermore expression and 
synthesis of growth factors and ECM components are significantly increased in the 
corneo-scleral ring and in the ON of 8 week old DCN-/- mice compared to WT littermates. 
Tangential sections of the glial lamina of 12 week old DCN deficient mice showed 
increased staining intensity for GFAP and changes in astrocyte morphology, indicating 
that astrocytes of this region undergo reactivation. Activation of the pAKT/AKT pathway 
was reduced in the TM, the retina and the ON of 12 week old DCN-/- mice.  
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IOP measurements and quantification of ON axons showed that DCN-/- mice in a pure 
CD1 background also have elevated IOP and less ON axons than WT littermates.  
 
5.2 Negative reciprocal effects of TGF-β2, CTGF and DCN in cell types 
involved in the pathogenesis of POAG 
 
TGF-β2 and CTGF have been found in elevated levels in the AH of POAG patients 
(Inatani et al., 2001; Ochiai and Ochiai, 2002; Picht et al., 2001; Tripathi et al., 1994b; 
Yamamoto et al., 2005). Moreover, a lens specific overexpression of CTGF leads to 
glaucomatous changes in mice (Junglas et al., 2012). TGF-β and CTGF can contribute 
to an accumulation of ECM components in the TM by increasing their expression and by 
inhibiting proteins that degrade ECM components (Fuchshofer and Tamm, 2009) and 
thereby cause an elevation of IOP. ONH astrocytes react to treatments with TGF-β2 with 
an increased expression of ECM components (Fuchshofer et al., 2005; Neumann et al., 
2008; Zode et al., 2011) and this upregulation is mediated via CTGF (Fuchshofer et al., 
2005). This leads to the assumption that both molecules play an essential part in the 
pathogenesis of POAG when present in pathological amounts. Since TGF-β2 and CTGF 
are present in the healthy eye (Tomarev et al., 2003) and TGF-β is essential for the 
immune privilege of the eye (Streilein, 1999a), there have to be regulators of TGF-β2 
and CTGF that are able to create a balance of physiological growth factor levels in the 
eye. One possible antagonist of TGF-β2 and CTGF could be DCN that is expressed in 
ocular tissue. DCN is able to bind TGF-β (Yamaguchi et al., 1990) and CTGF (Vial et al., 
2011) and can thereby inhibit their biological activity. In 2014 our group could show, in 
cooperation with D. Overby (Imperial College, London, UK), that SC cells of 
glaucomatous donors express significantly less DCN than SC cells of healthy donors 
(Overby et al., 2014b). In this study we could show proof that in POAG patients might be 
an imbalance between TGF-β2, CTGF and DCN. We could show that the DCN is 
dramatically reduced in the whole chamber angle, especially in the TM and in the 
endothelium of SC, in POAG eyes compared to healthy donors.  
In vitro reciprocal effects of TGF-β2, CTGF and DCN have not been studied up till now 
in human TM cells, human ONH astrocytes or murine ON astrocytes. In other cell types 
the influence of TGF-β on DCN levels was investigated and results indicate that it is cell 
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type dependent. TGF-β treatment leads to a decreased DCN expression in human skin 
fibroblasts and human chondrocytes (Kahari et al., 1991; Roughley et al., 1994) while 
DCN expression is upregulated after TGF-β treatment in murine osteoblasts and rat 
mesangial cells (Takeuchi et al., 1993). Effects of CTGF on DCN levels have not been 
studied yet.  
In this study we could demonstrate that treatment with TGF-β2 and CTGF leads to a 
downregulation of DCN expression and synthesis in all investigated cell types. These 
results led to the assumption that the reduced DCN levels observed in TM and SC 
endothelium are a result of an increased occurrence of TGF-β2 and CTGF. Decreased 
expression and synthesis of DCN in the TM could lead to an enhanced activity of TGF-β 
and CTGF which would result in an increased deposition of ECM material. Lack of DCN 
could also cause a disorganization of ECM proteins in the TM and in the ONH, since 
DCN is essential for binding and arranging collagen fibers (Scott, 1996; Weber et al., 
1996). 
On the other hand TGF-β can be negatively regulated by DCN via direct binding in 
Chinese hamster ovary cells or via upregulation of FBN1 synthesis in endothelial cells 
(Schonherr et al., 2005; Yamaguchi et al., 1990). In this study DCN treatment led to a 
significant downregulation of expression of TGF-β1, 2 and CTGF in all investigated cell 
types. Negative influence of DCN on the biological activity of CTGF via direct binding 
has been reported (Vial et al., 2011), but there is no data on the influence of DCN on the 
expression of CTGF yet.  
By reducing the expression and synthesis of TGF-β and CTGF, DCN should be able to 
lower their profibrotic effects. We could give first proof of this statement by showing 
reduced deposition of FN and Col IV after DCN treatment. For further proof the effects of 
DCN on stress fiber formation and the actin cytoskeleton of TM cells should be 
observed. The fast effect of DCN on the expression of TGF-β and CTGF prompts that 
DCN binds both growth factors directly in TM cells and ON astrocytes.  
Treatment of murine ON astrocytes with DCN led to a significant increase of the 
pAKT/AKT ratio 6 h after treatment, meaning that the pAKT/AKT signaling pathway is 
activated by DCN in these cells. Activity of this pathway has previously been reported for 
human brain derived astrocytes (Garwood et al., 2015), but not in astrocytes of the ON 
and there is no data of the effect of DCN on pAKT/AKT signaling in astrocytes. 
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Activation of the pAKT/AKT pathway by DCN leads to an increased synthesis of FBN1 in 
in rat kidney fibroblasts (Schaefer et al., 2007). FBN1 can actively interfere with TGF-β 
by preventing the release of active TGF-β from the latent TGF-β complex (Annes et al., 
2003; Schonherr et al., 2005). Mutations of FBN1 cause Marfan syndrome (Dietz et al., 
1991) and about 2% of Marfan patients are affected by a not categorized type of 
glaucoma (Faivre et al., 2007). This leads to the assumption that the mutation of FBN1 
leads to hyperactivity of TGF-β and could thereby favor the onset of glaucoma. By 
inhibiting the pAKT/AKT pathway we demonstrated that DCN regulates TGF-β1, 2 and 
CTGF expression via this pathway in murine ON astrocytes. The study does not 
completely answer the question whether the effect on CTGF is a direct one or mediated 
by the down regulation of TGF-β or an altered activity of TGF-β due to changes in 
synthesis of FBN1. Since we could observe an inhibitory effect on DCNs regulation of 
TGF-β and CTGF by triciribine after 24 h, it is very likely that DCN directly regulates 
TGF-β and CTGF via AKT signaling. There is evidence that phosphorylated AKT can 
bind to Smad3 and inhibit its phosphorylation, resulting in an inhibition of TGF-β 
signaling (Conery et al., 2004).  
All results clearly indicate that TGF-β, CTGF and DCN negatively regulate each other, in 
cell types involved in POAG. The results harden our hypothesis that a balance between 
TGF-β, CTGF and DCN is essential to prevent the onset and progression of POAG.  
 
5.3 DCN regulates ECM expression and synthesis in human TM cells 
and astrocytes 
 
Increased expression and synthesis of ECM components in the TM play an essential 
part in POAG and can contribute to an increase of IOP (Gottanka et al., 1997; Lutjen-
Drecoll et al., 1981; Tamm and Fuchshofer, 2007). Multiple studies demonstrated that 
TGF-β and CTGF induce expression and synthesis of ECM components in various cell 
types including human TM cells (Ignotz and Massague, 1986; Junglas et al., 2009; 
Varga et al., 1987). In human corneal fibroblasts transfection with DCN inhibited the 
profibrotic effect of TGF-β1 (Mohan et al., 2010). Due to that we hypothesized that DCN 
acts as an antagonist of the profibrotic effect mediated by TGF-β and CTGF in cell types 
involved in the pathogenesis of POAG. Treatment of human TM cells, human ONH 
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astrocytes and murine ON astrocytes with DCN resulted in a decreased expression and 
synthesis of FN and Col IV. In accordance to our results Hill et al. published that DCN 
can reduce TGF-β2 induced IOP elevation through fibrolysis in the TM via upregulation 
of MMP2 and MMP9 and downregulation of TIMP2, indicating that DCN is able to 
reverse established fibrosis in the TM (Hill et al., 2015). Due to its ability to regulate 
MMP-2, -9 and TIMP2 the absence of DCN should result in an imbalance of ECM 
production and degradation. DCN deficiency leads to an upregulation of TIMP2 in fetal 
membranes (Wu et al., 2014), but there is no data on MMP regulation in DCN-/- mice yet. 
Upregulation of TIMP2 induces accumulation of ECM material and a negative effect of 
DCN deficiency on the expression of MMPs would cause reduced outflow facility in the 
TM. Due to that expression and synthesis of MMPs and TIMP2 should be analyzed in 
the TM of DCN-/- mice. Our RNA sequencing data already gave a first lead that MMP2 
expression is affected by the absence of DCN in the TM, but intriguingly MMP2 
expression was increased in DCN-/- mice. In addition it would be of interest to analyze 
the effects of DCN treatment on SMA expression in human TM cells, since SMA is 
induced in the TM by CTGF and can contribute to an elevation of IOP by increasing TM 
cell actomyosin contractility (Junglas et al., 2012; Junglas et al., 2009).  
The results of this thesis strongly indicate that DCN could contribute to a reduction of 
ECM material in the TM and to a lowering of IOP. Thereby it could prevent the onset or 
the progression of POAG. It could also reduce fibrosis of the ONH by decreasing 
deposition of ECM material by astrocytes and so reduce RGC death. The effect of DCN 
on LC cells has not been studied up till now.  
 
5.4 An imbalance between CTGF and DCN favors the onset of POAG 
 
In this study we demonstrated that in the chamber angle of donors affected by POAG 
DCN protein was dramatically reduced in all regions of the TM and in the endothelium of 
SC, but we did not investigate whether this reduction of DCN is due to elevated levels of 
CTGF or TGF-β. Further proof of an imbalance between TGF-β2, CTGF and DCN was 
published recently. It was shown that SC cells of glaucomatous donors express 
significantly more TGF-β and CTGF while they express significantly less DCN than SC 
cells of healthy donors (Overby et al., 2014). This hints that a sensitive balance between 
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DCN, TGF-β2 and CTGF is essential to prevent the onset of POAG. Disturbance of this 
balance in favor of TGF-β2 and CTGF could strongly promote the onset and 
pathogenesis of POAG. For that reason it would be of great interest to analyze models 
and experimental setups that combine, for example, an overexpression of CTGF and a 
lack of DCN or to check if the profibrotic effects of CTGF and TGF-β can be reversed by 
adding DCN to the system.  
 
In mice a lens-specific overexpression of CTGF causes increased IOP and RGC death 
by elevating ECM synthesis in the TM and altering the actin cytoskeleton of TM cells. 
This makes βB1-CTGF mice an acknowledged model for POAG (Junglas et al., 2012). 
Since we could demonstrate a negative regulatory effect of CTGF on expression and 
synthesis in TM cells and astrocytes we concluded that an overexpression of CTGF in 
vivo should alter expression and synthesis of DCN.  
This is the first study to elucidate the influence of CTGF on DCN expression and 
synthesis in different tissues of the eye in vivo. DCN expression and synthesis was 
significantly reduced in the corneo-scleral ring of βB1-CTGF mice compared to WT 
littermates. This shows that CTGF has a negative effect on the expression and synthesis 
of its antagonist DCN which could lead to a potentiation of CTGF expression and 
synthesis. That CTGF is capable of auto induction has been reported in human TM cells 
before (Junglas et al., 2009).  
Regarding the ON we could not detect DCN mRNA or protein in ONH samples but in 
samples containing the whole ON. DCN mRNA and protein were not altered in the ON of 
βB1-CTGF mice compared to WT littermates. Most likely the endogenous CTGF 
secreted by the lens does not reach the ON and therefore does not influence expression 
or synthesis of DCN.  
Since we observed reduced amounts of DCN protein in the chamber angle of donors 
affected by POAG we posed ourselves the question whether a knockout of DCN in vivo 
will lead to glaucomatous changes in the TM and in the ONH and if these would induce 
an elevation of IOP and a loss ON axons. To answer these questions we analyzed DCN 
deficient mice and their wildtype littermates of different ages with focus on IOP, axon 
numbers, gene expression and protein synthesis in the relevant tissues. 
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An increased IOP is the major risk factor to develop POAG (Collaborative-Normal-
Tension-Glaucoma-Study-Group, 1998; Gordon et al., 2002; Johnson et al., 2002; Leske 
et al., 2003) and the loss of axons in the optic nerve is the main characteristic of this 
optic neuropathy. So it was one main goal of this study to analyze the IOP of DCN-/- 
mice and WT mice of different ages and to quantify optic nerve axons. Thus we wanted 
to ascertain if DCN-/- mice might be a new and useful animal model for POAG. To 
exclude that structural changes in the chamber angle and the TM, that do not take place 
in POAG patients, lead to blocking of AH outflow and thereby increase IOP, we 
examined sagital sections of eyes of DCN-/- and WT mice of different ages. No structural 
changes were observable by light microscopy. Chamber angles of all animals were open 
and no synechia or pigment dispersion were obeserved that could block AH outflow and 
thereby increase IOP. SC was developed normally in DCN-/- mice so that AH is able to 
drain via the conventional outflow pathway.There were no noticable changes in cornea, 
retina, lens, papilla or optic nerve, leading to the conclusion that a knockout of DCN 
does not negatively affect eye development.  
In other glaucoma models, elevation of IOP is often caused by structural changes that 
block AH outflow. In DBA2J mice AH outflow is reduced due to iris atrophy and the 
associated formation of synechias, making these mice a good model for secondary 
angle-closure glaucoma (John et al., 1998). Mice with an embryonal conditional 
knockout of angiopoetin (ANGPT) 1 and 2 do not develop a SC, leading to an early and 
extreme increase of IOP. These mice show a protruding bulbus at 21 days and IOP is 
increased up to 4 fold at an age of 10 weeks (Thomson et al., 2014) making these mice 
a usable model for lowering IOP but not for POAG, since POAG is age associated and is 
characterized by a more slowely increase of IOP.  
Beside genetic based glaucoma models, an increased IOP can be induced by 
mechanically  blocking the AH outflow, e.g. via injection of latex microspheres or 
polysteren beads (Sappington et al., 2010; Weber and Zelenak, 2001) and ON crush to 
induce RGC death, are commonly used models for glaucoma. In contrast to POAG both 
those models induce spontaneus damage at the TM or at the ONH and do not allow to 
observe the time course of IOP elevation or RGC death, which can be observed in a 
genetical glaucoma model with a slow onset of glaucoma.  
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In this study we measured IOP changes in DCN-/- and WT mice over one year. IOP was 
not changed in 4 week old DCN-/- animals compared to WT mice of the same age, but 
was significantly higher in all DCN-/- mice of older age groups. An increase of IOP with 
age was observed in WT and DCN-/- mice but the increase was 1.6 times higher over  
12 month in DCN-/- mice than in WT mice. An increase of IOP with age has been 
reported previously in humans (Qureshi, 1995; Wong et al., 2009) and in mice (Cone et 
al., 2012).  
The knockout of DCN lead to a significant loss of ON axons in mice older than 8 weeks. 
Intriguingly the increase of IOP over time did not, as expected, result in a decreasing 
number of optic nerve axons. 8 week old DCN-/- mice had the same number of ON nerve 
axons than WT littermates, but allready at an age of 12 weeks axon number was 
significantly reduced in DCN-/- mice. We could observe a difference of 21% between  
12 week old WT and DCN-/- mice, a difference of 16.5% between 6 month old WT and 
DCN-/- mice and a difference of 14.5 % between 12 month old WT and DCN-/- mice. 
Axon numbers decreased slightly over time in WT mice but were almost stable in  
DCN-/- mice. These results might probably be due to small sample sizes and should be 
verified further in future experiments since loss of optic nerve axons with age has been 
reported multiple times in different species (Cepurna et al., 2005; Fortune et al., 2014; 
Jonas et al., 1992; Mikelberg et al., 1989). Stable axon numbers over age could also be 
due to the mixed background of DCN-/- and WT animals. CD1 mice, for example, have 
more optic nerve axons than C57/BL6 mice (Cone et al., 2010), so one can conclude 
that genetic background strongly influences axon numbers.  
Analysis of CTGF levels in the corneo-scleral ring of DCN-/- again hardened the 
hypothesis that an imbalance of DCN and CTGF favors the onset of POAG. Expression 
and synthesis of CTGF and TGF-β were significantly higher in the corneo-scleral rings of 
8 week old DCN-/- mice compared to WT mice. It was shown before that DCN can bind 
CTGF and is so able to inhibit its profibrotic effects and that DCN null myoblasts are 
more sensitive to CTGF, showing in an increased accumulation of FN (Vial et al., 2011), 
but there is no data on how DCN influences the expression of CTGF and vice versa.  
Seeing that in vitro murine ON astrocytes showed negative reciprocal effects of TGF-β2, 
CTGF and DCN we investigated if the knockout of DCN leads to expression changes in 
the ON. Expression of TGF-β1, TGF-β2 and CTGF was significantly higher in the ON of 
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DCN-/- compared to WT mice, indicating that cell types in this tissue react to DCN 
deficiency with an upregulation of growth factor expression.  
 
5.5 ONH astrocytes of DCN-/- mice show signs of reactivation 
 
Reactivation of astrocytes in the ONH is a typical observation in POAG. In human ONH 
with chronically elevated IOP and moderate or advanced glaucomatous axonal damage 
astrocytes show thickening of processes, hypertrophy of the cell body and an increased 
immunoreactivity for GFAP (Hernandez and Pena, 1997; Varela and Hernandez, 1997; 
Wang et al., 2002). 
In tangential sections of the region of the glial lamina of 12 week old DCN-/- mice we 
observed similar changes, indicating astrocyte reactivation. The same observation has 
already been made in other murine glaucoma models (Lye-Barthel et al., 2013; Son et 
al., 2010), leading to the conclusion that reactivation of astrocytes in the region of the 
glial lamina is a typical phenomenon in mice, too. Moreover it again shows the usability 
of DCN-/- mice as a model for POAG.  
Long-term studies with a genetic model, like the DBA/2J mice, show a constantly 
significant increased GFAP expression in the ONH, hinting at an association of the 
reactive phenotype with severe axon loss. This suggestion is supported by findings that 
the recovery of the astrocytic organization is dependent on the grade of axon loss. 
Astrocytes, after a moderate axon loss, have the capability to re-establish the 
honeycomb arrangement in the glial lamina (Sun et al., 2013). After an optic nerve 
crush, astrocytes do not regain the structure of a glial lamina and lead to the formation of 
a glial scar (Sun et al., 2010). In this study we could not observe further axon loss over 
time after 12 weeks, so possibly the reactivation of astrocytes at that time point has a 
beneficial effect on axon survival. To prove this hypothesis, further experiments have to 
be carried out in which the reactivation status of astrocytes and the structure of the glial 
lamina have to be analyzed at older ages.  
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5.6 DCN deficiency reduces pAKT/AKT signaling 
 
DCN is able to influence the activity and thereby also the expression of TGF-β and 
CTGF via the pAKT/AKT signaling pathway (Schonherr et al., 2005). Our in vitro 
experiments showed that DCN activates pAKT/AKT signaling in murine ON astrocytes. 
Vice versa the absence of DCN should lead to a decreased activity of this pathway. 
Activation of the named signaling pathway results in upregulation of FBN1 synthesis. 
FBN1 controls TGF-β activation, as it controls the assembly and stability of the latent 
TGF-β complex (Annes et al., 2003). Hence reduced activity of the pAKT/AKT pathway 
should lead to elevated activity of TGF-β.  
Immunohistochemical staining against pAKT showed a lower signal in the retina and in 
the chamber angle of DCN-/- mice than in WT littermates. pAKT signal in the retina 
spanned from the nuclear layer to the outer plexiform layer, so probably Mueller cells are 
the main source of pAKT in the retina. Double staining against pAKT and GFAP or pAKT 
and glutamine synthetase should be carried out to clarify this. 
Signal for pAKT was lower in ON cross sections of DCN-/- animals, too. Double staining 
against GFAP and pAKT in tangential sections of the glial lamina showed co-localization 
of both proteins, proofing that astrocytes of that region engage in pAKT/AKT signaling.  
It would be of great interest to investigate if a decreased pAKT/AKT signaling in 
astrocytes of the glial lamina leads to an increase of TGF-β and CTGF expression and 
synthesis. First attempts to isolate RNA and protein of mouse ONHs were successful, so 
these analyses will be carried out in the future.  
In vitro blocking of the pAKT/AKT signaling pathway in human brain derived astrocytes 
does not lead to changes in viability or cell number, but leads to significant increase in 
GFAP synthesis (Garwood et al., 2015). Therefore the increased signal for GFAP in the 
glial lamina of DCN-/- mice might be a result of the lowered activity of the pAKT/AKT 
pathway. In vivo an adeno-associated virus transduction with a gene encoding a 
constitutively active form of Akt/PKB reduced apoptotic cell death in a highly destructive 
neurotoxin model by activating  intracellular neurotrophic signaling pathways (Ries et al., 
2006). This hints that a decreased activity of pAKT/AKT signaling might have negative 
effects on the expression and synthesis of neurotrophic factors and could thereby 
contribute to RGC death.  
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Analysis of the pAKT/AKT ratio in the anterior eye segment, the retina and the ONH has 
to be carried out to ensure changes in the activity of this pathway in DCN-/- mice. 
Additionally it is of interest to investigate if these changes have influence on expression 
and synthesis of neurotrophic factors in vivo and in vitro.  
 
5.7 DCN deficiency leads to expression changes of pathways and 
genes associated with glaucoma in the corneo-scleral ring  
 
In addition to the expression and synthesis changes in TGF-β2 and CTGF in the corneo-
scleral ring we further proved an elevated expression and synthesis of FN and Col IV in 
the corneo-scleral rings of DCN-/- animals. Both ECM molecules are structural 
components of the healthy TM (Tamm, 2009; Tawara et al., 1989; Ueda et al., 2002), 
but are known to be elevated in the TM during POAG (Lutjen-Drecoll et al., 1981) and 
most likely contribute to an elevation of IOP by increasing outflow resistance to AH 
(Tamm and Fuchshofer, 2007). The increase of FN and Col IV in the corneo-scleral ring 
of DCN-/- mice is most likely due to the elevated levels of TGF-β2 and CTGF in that 
region since both growth factors are known to upregulate ECM expression and synthesis 
in human TM cells and also decrease the expression and synthesis of ECM degradation 
proteins (Fuchshofer and Tamm, 2009; Junglas et al., 2009).  
RNA-sequencing was performed to create an overview over genes and pathways that 
are differentially expresses in DCN-/- and WT mice’s corneo-scleral rings. Due to the fact 
that a first elevation of IOP was observed in 12 week old DCN-/- mice, mice of that age 
were used for analysis.  
Results were analyzed using the DAVID software to check for significantly enriched 
gene ontology terms (GO terms). Among the significantly enriched GO terms were for 
example extracellular matrix organization and actin cytoskeleton organization. 
Reorganization of the ECM is a critical feature of POAG. In the TM deposition of ECM is 
increased and fibrous plates are formed which contribute to an increased outflow 
resistance (Lutjen-Drecoll et al., 1981; Tamm and Fuchshofer, 2007). In the ONH 
remodeling of the ECM leads to stiffening of the peripapillary sclera (Coudrillier et al., 
2012), thickening of the connective tissue sheaths around the capillaries (Tektas et al., 
2010) and a restructuring of the LC (Pena et al., 1998; Quigley et al., 1991b; Quigley et 
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al., 1983). Changes in the actin cytoskeleton in POAG show manly in stiffening of the 
TM (Last et al., 2011) and can contribute to reducing AH outflow by an increased 
contractility of TM cells induced by CTGF (Junglas et al., 2012). The Wnt receptor 
signaling pathway seems also to be altered in the corneo-scleral ring of DCN deficient 
mice. Wnt signaling is associated with glaucoma via myocillin (Myoc), which is an 
important modulator of this pathway (Kwon et al., 2009a). It is documented that 
dominant mutations in the MYOC gene may lead to juvenile- or adult onset POAG and 
are found in 3 to 4% of POAG patients (Fingert et al., 1999; Fingert et al., 2002). 
Additionally it could be shown that inhibition of Wnt signaling by secreted frizzled-related 
protein-1 (sFRP-1) increases IOP in ex vivo perfusion-cultured human eyes and that 
sFRP-1 is overexpressed in glaucomatous TM cells (Wang et al., 2008). TGF-β2 is also 
able to inhibit the Wnt pathway (Webber et al., 2016). So the crosstalk between Wnt- 
and TGF-β signaling very likely could contribute to an elevation of IOP in POAG.  
After narrowing all genes down to genes with an expression ratio differences of either 
greater than 0.5 log2-fold or less than -1.0 log2-fold and a p-value of ≤ 0.05, the resulting 
258 genes we carried out literature screening to identify genes that had been reported in 
the context of glaucoma previously. We found literature references for 21 genes related 
to glaucoma. This hints that the absence of DCN not only affects TGF-β and CTGF, but 
also other genes that could play a role in the pathogenesis of POAG, like wnt4 (Yuan et 
al., 2013) or tgm2 (Tovar-Vidales et al., 2008). Interactions of DCN and the other genes 
related to glaucoma were not investigated in this study. 
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Gene Reference  
branched chain amino acid transaminase 1 (Yasuda et al., 2014) 
leucine rich repeat and immunoglobin-like 
domain-containing protein 1 
(Fu et al., 2009) 
versican (Lukas et al., 2008) 
fibromodulin  (Steinhart et al., 2014) 
BCL2 associated X protein (Levkovitch-Verbin et al., 2013) 
ras homolog gene family member A (Saracaloglu et al., 2016) 
transporter associated with antigen 1 (Hysi et al., 2014) 
uncoupling protein 2 (Yang et al., 2015) 
transporter associated with antigen 2 (Hysi et al., 2014) 
collagen type IV (Tektas and Lutjen-Drecoll, 2009) 
EGF receptor (Liu et al., 2006) 
transglutaminase 2 (Tovar-Vidales et al., 2008) 
exportin for tRNA (Fingert et al., 2011) 
signal transducer and activator of transcription 
6 
(Thanos and Naskar, 2004) 
small mother against decapentaplegic 7  (Fuchshofer et al., 2009) 
wnt4 (Yuan et al., 2013) 
C-X-C motif chemokine 10 (Freedman and Iserovich, 2013) 
signal transducer and activator of transcription 
1 
(Yang et al., 2007) 
matrix metalloproteinase-2 (Ashworth Briggs et al., 2015) 
tafazzin (Raghunathan et al., 2013) 
tropomyosin  (Zhao et al., 2004) 
Table 30: Genes associated with glaucoma altered in the corneo-scleral ring of DCN
-/-
 mice and 
sources. 
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5. 8 Outlook  
 
In vitro the effects of DCN on the synthesis of TGF-β2 in human TM cells, human ONH 
astrocytes and murine ON astrocytes should be investigated. By silencing of TGF-β2 the 
question if the effect of DCN on CTGF expression and synthesis is direct one could be 
answered. This setup was already used in our group to show that CTGF alone is able to 
induce ECM production in human TM cells (Junglas et al., 2009). Via silencing of TGF-β 
and CTGF possible direct effects of DCN on ECM production could be analyzed. Since 
we saw signs of reactivation of ONH astrocytes in DCN-/- mice it would be interesting to 
find out if DCN affects GFAP expression and synthesis of GFAP, morphology and 
migration in murine ON astrocytes, because those are signs of astrogliosis (Hernandez 
and Pena, 1997; Varela and Hernandez, 1997; Wang et al., 2002).  
We demonstrated first proof that DCN synthesis is reduced in the outflow tissue of 
POAG patients. Analyzing expression and synthesis of DCN, TGF-β2 and CTGF in 
human TM cells of healthy and glaucomatous donors could give deeper insight in the 
reciprocal effects of these proteins in health and POAG. In this study an imbalance 
between CTGF, TGF-β2 and DCN in the region of the TM could be shown in two 
different mouse models that show an elevated IOP and loss of optic nerve axons. Hence 
we state that a shift of the balance between those factors in favor of CTGF and TGF-β2 
promotes the onset and progression of POAG. 
Mice with a lens-specific overexpression of CTGF are an acknowledged model for 
POAG. They show increased ECM production in the TM, elevated IOP and loss of  
ON axons (Junglas et al., 2012). This study shows that in vitro DCN is able to reduce 
expression and synthesis of CTGF and that it can contribute to reduction of  
ECM expression and deposition. In addition to our work it has been reported that 
intracameral injection of DCN reduces TGF-β2 induced IOP and RGC loss by reducing 
fibrotic components in the TM (Hill et al., 2015). In this study high amounts of  
DCN (3 x 17.5 µg) were necessary to lower IOP, so administration of DCN via a different 
way might be desirable. AAV-5 DCN gene therapy significantly inhibits corneal scarring 
(Mohan et al., 2011) due to an inhibitory effect of DCN on TGF-β in corneal fibroblasts 
(Mohan et al., 2010). This indicates that viral gene transfer of DCN in the eye is a usable 
way to reduce the profibrotic effects of TGF- β. Delivering DCN via an adeno virus to the 
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eyes of βB1-CTGF mice would be a good model to assess the possible use of DCN as a 
therapeutic against POAG. IOP, axon numbers in the ON and expression and synthesis 
of ECM components in the TM should be analyzed in untreated and DCN adeno virus 
treated eyes.  
Regarding DCN-/- mice future studies should investigate possible structural changes in 
the TM on electron microscopy level that could contribute to the observed increase in 
IOP. Increasing n numbers of Axon number quantification would probably elucidate if 
axon number really do not decrease with age in WT and DCN-/- mice. Observing RGC 
death using e.g. TUNEL assay and analyzing functionality of the retina via 
electroretinography could help answering the question whether DCN-/- mice are a usable 
model of POAG.  
This study gave first evidence that pAKT/AKT signaling is reduced in the eyes of DCN 
deficient mice, but it did not yet investigate changes in pAKT/AKT ratio or possible 
effects of decreased signaling on expression and synthesis of neurotrophic factors. 
Since deprivation of neurotrophic factors is a major cause of RGC death (Pease et al., 
2000; Quigley et al., 2000), and AKT signaling seems to involved in regulation of 
neurotrophic factors (Ries et al., 2006) a reduced activity could contribute to increased 
RGC death.  
In addition all experiments carried out in this study could be repeated in CD1 WT and 
CD1 DCN-/- animals to find out if the effects of DCN deficiency are enhanced in mice in a 
pure CD1 background, since it has been shown before that CD1 mice are more 
susceptible to glaucomatous damage than other mice strains (Cone et al., 2010; Cone et 
al., 2012). 
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6. Conclusion 
 
Overall this is the first study to report negative reciprocal effects of DCN, TGF-β and 
CTGF in cell types involved in the pathogenesis of POAG. The ability of DCN to reduce 
TGF-β, CTGF and ECM components in TM cells and astrocytes of the ON makes it a 
highly interesting protein for glaucoma research. DCN could contribute to fybrolisis in the 
TM and in the ONH and thereby be able to slow down the progression or even prevent 
the onset of POAG.  
In vivo we found evidence that a disturbance of the balance between DCN and CTGF 
favors the onset and progression of POAG. While DCN synthesis is reduced in the 
human glaucomatous chamber angle, DCN deficiency leads to glaucomatous changes 
in mice. DCN-/- mice have an elevated IOP and show loss of optic nerve axons while 
having no obvious morphological changes in the chamber angle, meaning that they fulfill 
the main criteria of POAG. Hence we postulate that DCN-/- mice are a new model for 
POAG. 
All results of this study strongly hint that DCN is a good candidate for a new therapeutic 
approach to treat or prevent POAG.        
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µg microgram 
µl microliter 
µm micrometer 
AAV-5 adeno associated virus 5  
AC anterior chamber 
AGS astrocyte growth supplement 
AH aqueous humor 
AKT AKT serine/threonine kinase 
AP alkaline phosphatase 
APS ammonium persulfate 
bp base pairs 
BSA bovine serum albumin 
CB ciliary body 
cDNA complementary deoxyribonucleic acid 
CM ciliary muscle 
Co cornea 
Col collagen 
Ct cycle threshold 
CTGF connective tissue growth factor 
CTM corneoscleral trabecular meshwork 
DAPI 4′,6-Diamidin-2-phenylindol 
DCN decorin 
DMEM Dulbecco's Modified Eagle's Medium 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
dNTPs deoxynucleotide 
DTT dithiothreitol 
ECM extracellular matrix 
EDTA ethylenediaminetetraacetic acid 
EL elastin 
EM electron microscopy  
EtBr ethidium bromide 
ETOH ethanol  
FCS fetal calve serum  
FBN1 fibrillin 1 
FN fibronectin  
g gram 
GAG glycosaminoglycan 
GCL ganglion cell layer 
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GFAP glial fibrillary acid protein  
GNB2L guanine nucleotide binding protein 
GO gene ontology 
H2O water  
h hour 
HCl hydrochloric acid  
Hg mercury  
HRP horseradish peroxidase 
IFN interferon  
IgG immune globulin G 
IL interleukin  
INL inner nuclear layer 
IOP intraocular pressure 
JCT juxtacanalicular meshwork  
kg kilogram  
l iris 
LAP latency Associated Peptide 
LC lamina cribrosa 
LRR leucine rich repeat 
LTBP latent TGF-β-binding protein 
M molar 
mA milliampere  
min minute  
ml millilitre  
mm millimeter 
mM millimolar 
MMP matrix metallo proteinase  
mRNA messenger ribonucleic acid 
mTOR mammalian target of rapamycin  
Neo neomycin 
ng nanogram  
OD optical density  
ON optic nerve  
ONH optic nerve head 
ONL outer nuclear layer  
PAI-1 plasminogen activator inhibitor 1  
PBS phosphate-buffered saline 
PCR polymerase chain reaction  
PFA paraformaldehyde  
Pgk phosphoglycerate kinase 
Php phosphate  
POAG primary open angle glaucoma  
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PVDF polyvinylidene difluoride 
Re retina  
RGC retinal ganglion cell 
RIPA radioimmunoprecipitation assay  
RNA ribonucleic acid 
RPE retinal pigment epithelium  
RPL32 ribosomal protein L32 
rpm rounds per minute  
RT room temperature  
SC Schlemm’s canal  
SDS sodium dodecyl sulfate 
SLRP Small leucine rich proteoglycan  
SMAD small mothers against decapentaplegic 
SS scleral spur 
TBE tris-borat-EDTA 
TBS tris-buffered saline 
TBST tris-buffered saline tween 20 
TEMED tetramethylethylendiamin 
TG transgenic 
TGF-β transforming growth factor β 
TGF-β R transforming growth factor β receptor  
TM trabecular meshwork  
UTM uveal trabecular meshwork  
UV ultra violet  
V volt  
WT wildtype 
α-SMA α-smooth muscle actin 
 
 
12. Erklärung 
135 
11. Acknowledgement / Danksagung  
 
Mein Dank gilt Prof. Dr. E. Tamm der es mir ermöglich hat meine Arbeit der letzten 
Jahre in seinem Labor auszuführen. Zudem bedanke ich mich herzlich für die 
Übernahme des Vorsitzes der Verteidigung.  
 
Des Weiteren danke ich Prof. Dr. S. Schneuwly für die Übernahme des Zweitgutachtens 
für diese Arbeit, sowie Prof. Dr. C. Wagner und Prof Dr. V. Egger für die Bereitschaft 
das Amt des Dritt- bzw. Ersatzprüfers zu übernehmen.  
P.D. Dr. A. Ohlmann danke ich herzlich für die Übernahme des Mentorats für meine 
Dissertation. Many thanks also go to PD Dr P. Russell for good advice on my thesis and 
for enabling me to work in his laboratory!   
 
Bei Prof. Dr. R. Iozzo und Prof. Dr. L. Schaefer bedanke ich mich für die Erlaubnis mit 
den DCN knockout Mäusen zu arbeiten.  
 
Ganz besonders möchte ich mich bei Prof. Dr. R. Fuchshofer bedanken, der mich in den 
letzten Jahren erstklassig betreut hat und das Erstgutachten für diese Arbeit 
übernommen hat. Ich habe sehr viel von ihm gelernt, nicht nur über die Forschung 
sondern auch über das Leben! Für viele lehrreiche aber auch unterhaltsame Stunden 
bin ich sehr dankbar! 
 
Zudem bedanke ich mich bei allen ehemaligen und aktuellen Mitgliedern der AG 
Fuchshofer, im Besonderen bei Dr. Sabrina Küspert, Gregor Weber und Andrea 
Dillinger, die mich durch fast die gesamte Zeit am Lehrstuhl begleitet haben und mir bei 
vielen Problemen und Problemchen mit Rat und Tat zur Seite standen. Hervorheben 
möchte ich auch Mutasem-Bellah Saman, Tamara Löffler und Franziska Scherl die im 
Rahmen ihrer Masterarbeiten wichtige Erkenntnisse zu meiner Arbeit beigetragen 
haben.  
 
12. Erklärung 
136 
Bei unseren guten Seelen des Labors, Sylvia Babl, Angelika Pach, Margit Schimmel und 
Elke Stauber möchte ich mich von ganzem Herzen für die gute Zusammenarbeit und die 
Unterstützung im Bereich Zellkultur und Histologie bedanken.  
In den letzten Jahren habe ich viele schöne Stunden im aber auch außerhalb des 
Labors mit den Mädels aus dem Büro verbracht, Danke dafür! Danke an Anja Schlecht 
für ruhige Stunden im Wald beim Bogenschießen und an Nikola Fath fürs gemeinsame 
auspowern in diversen Boulderhallen! Allen meinen Freunden die mir während der 
letzten Jahre in allen Situationen beigestanden und manchmal auch meine Launen 
ertragen haben danke ich von ganzem Herzen!  
 
Mein ganz spezieller Dank gilt Martin Wild, der meinen Weg die letzten Jahre in allen 
Höhen und Tiefen begleitet hat, mich immer wieder motiviert und aufgebaut hat und mir, 
egal wie und womit, immer geholfen hat. 
  
Aus tiefstem Herzen danke ich meinen Eltern Ilse und Wolfgang Schneider. Sie haben 
mir mein Studium ermöglicht und alle mein Entscheidungen stets unterstützt. Ohne Sie 
wäre ich nie so weit gekommen! Auch meinen Schwestern Anna und Franziska möchte 
ich herzlich für Unterstützung in allen Lebenslagen danken!   
12. Erklärung 
137 
12. Erklärung 
 
Hiermit erkläre ich, dass ich die vorliegende Dissertation selbstständig und ohne 
unerlaubte Hilfsmittel angefertigt habe. 
 
 
 
 
 
Regensburg, den 
Magdalena Schneider    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
